Introduction {#Sec1}
============

*Bidens pilosa* L. is a plant of the Asteraceae family and belongs to the *Bidens* genus, which comprises approximately 280 species (Holm et al. [@CR80]). *Bidens pilosa* is an annual plant and originated from South America, but it is now widely distributed in most pantropical areas of the world. Its variants include *pilosa* var., *minor* var., *radiata* var., *minor* var., *odorata* var., *alba* var., *bimucronata* var., *bisetosa*, *calcicola*, and *alausensis* (Holm et al. [@CR80]; Khanh et al. [@CR96]). This plant grows with numerous ridged branches, reaches over two meters under favorable conditions and is commonly called by many vernacular names, such as hairy beggartick; Spanish needles; devil needles; black jack; railway daisy; and pitchforks (Holm et al. [@CR80]; Mitich [@CR125]). The generic name *Bidens* came from the Latin and means "two teeth", *bis* means double or two, and *dens* means tooth, which refers to the typical twin barbs at the tip of the achene. *Pilosa* refers to the soft hair appearance. Leaves are opposite, petioled, pinnate, with 3--5 sharply serrated ovate leaflets, and are slightly hairy (Mitich [@CR125]). *Bidens pilosa* is easily recognized by its elongated budlike achenes that bear recurved or hooked bristles, a device that insures its dissemination. The branches and stems are marked with parallel lines or ridges that are smooth and green or with brown stripes (Holm et al. [@CR80]). The tiny inflorescence is a capitulum (congested head of flowers) with yellow centers and white ray petals and the achenes are blackish, narrow, ribbed, and sparsely bristled to smooth (Mitich [@CR125]). The seeds are dark brown or black, slender, reach 1 cm in length, and are clustered on the end of the stalk. The characteristics of *B. pilosa* seeds allow them to be widely dispersed by wind, and they adhere easily to clothes and animal fur. A single plant can produce 3000--6000 seeds, many of which germinate readily at maturity, facilitating three or four generations in some areas per year. The optimum temperature for seed germination is 15--40 °C, and seeds remain viable for years and germinate readily when buried in soil. Over 80 % of 2--5 year-old seeds germinate (Holm et al. [@CR80]). Due to its fast growth, this plant has been introduced in most parts of the world, preferentially in moist, shady locations. It has extensively invaded both cultivated and non-cultivated fields and plant ecosystems, causing problems in many food crops in most of the 40 countries where it grows (Holm et al. [@CR80]; Khanh et al. [@CR96]; Mitich [@CR125]).

The aim of this review is to present comprehensive information on the major chemical constituents of *Bidens pilosa*, its nutraceutical and ethnomedical uses in folk medicine as well as its major pharmacological and rare toxicological effects, considering both actual developments and relevant reports of the past years. In addition, we discuss its potential health benefits derived from biological activities of its chemical constituents. The focus is also on the need of evidence-based clinical trials to confirm efficacy. Reviews on the phytochemicals and pharmacology of *B. pilosa* have appeared only sporadically, of interest are reported (Connelly [@CR50]; Potawale et al. [@CR146]; Silva et al. [@CR163]; Young et al. [@CR202]).

Nutraceutical and worldwide medicinal uses {#Sec2}
==========================================

In South America, native Amazonians appreciate *Bidens pilosa* as an edible plant and an herbal tea (Kunkel [@CR102]). In Uganda and Africa, the fresh or dry shoots and young leaves are boiled in sour milk and consumed as for human food as vegetables (Holm et al. [@CR80]). In Kenya, *B. pilosa* is also used as a traditional leafy vegetable and to improve human health (Orech et al. [@CR142]). In the Himalayan region, its inhabitants harvest fresh leaves to prepare the beverage known as "Ladakhi tea" (Bhatt et al. [@CR17]). In Australia and Hawaii, the young shoot tips are used in tea and juice (Mitich [@CR125]). The nutritional contents of the upper parts of the *B. pilosa* plant are detailed in Table [1](#Tab1){ref-type="table"}.Table 1Nutritional contents/composition in upper parts of *B. pilosa* (values per 100 g edible portion)PlantE (kcal)P (g)C (g)F (g)M (%)F (g)A (g)Ca (g)P (g)I (µg)C1 (mg)Z (µg)R (mg)Va (µg)As (mg)Fo (µg)Ma (mg)Raw43.03.88.40.585.13.92.20.340.06740.41.80.800.298523351135Dried33.02.86.00.688.61.32.00.110.0392.3--------------(--) not calculated*E* energy, *P* protein, *C* carbohydrate, *F* fat, *M* moisture, *F* fiber, *A* ash, *Ca* calcium, *P* phosphorus, *I* iron, *C1* carotene, *Z* zinc, *Va* vitamin A, *As* ascorbic acid, *R* ribolflavin, *Ma* magnesium*Sources* Young et al. ([@CR202]), Orech et al. ([@CR142]), Food and Nutrition Division ([@CR67]), and Uushiku et al. ([@CR184])

Worldwide, all parts of *B. pilosa* have a long tradition as folk medicine to treat various ailments, with indications varying from one country to the other. The entire plant was appreciated in the sixteenth and seventeenth centuries in Europe for its astringent, diaphoretic, and diuretic properties (Mitich [@CR125]). Roots, leaves and seeds possess anti-bacterial, anti-dysenteric, anti-inflammatory, anti-malarial, anti-septic, anti-cancer, anti-pyretic, liver-protective, blood-lowering, hypoglycemic, diuretic, anti-diabetic, and hepato-protective effects (Towers et al. [@CR181]; Subhuti [@CR167]). *Bidens pilosa* is an important traditional medicine in South Africa that has been used by various cultural groups for a wide range of treatments. For instance, a leaf decoction is used to treat headaches, ear infections, kidney problems, and flatulence. The leaf extract is also used to cure malaria, stomach and mouth ulcers, diarrhea, hangover; the whole plant is also used as a poison antidote (Subhuti [@CR167]). However, in the sub-Sahara, where fresh or dry shoots and young leaves of *B. pilosa* are sometimes used as human food, these are believed to contribute to the etiology of human esophageal cancer (Mirvish et al. [@CR122], [@CR123]). In China, *B. pilosa* is traditionally considered to cure enteritis, bacterial dysentery, and pharyngitis (Wong-Leung [@CR194]; Zhang [@CR205]). Young leaves and flowers have been used in Mexican folk medicine to treat stomach disorders, hemorrhoids, and diabetes (Alvarez et al. [@CR7]). In Japan, the traditional drug known as Kampo-tea^®^ is made from dried *B. pilosa* powder and used as an ingredient in tea for livedo reticularis with summer ulceration, a cutaneous disease (Masuzawa et al. [@CR118]); also the extract of the aerial parts prepared with boiling water is thought to have anti-inflammatory and anti-allergic properties (Horiuchi and Seyama [@CR81]). *Bidens pilosa* is known as Picão preto in Brazil, and is widely used as a medicinal plant for treating inflammation, arterial hypertension, ulcers, diabetes and all types of infections (Taylor [@CR173]).

*B. pilosa* has been used as a medicinal plant for a long time, and the anti-microbial activities of its juice and aqueous extracts have been well demonstrated (Wong-Leung [@CR194]; Bushnell et al. [@CR26]). The leaves are commonly used for treating sore eyes, abdominal distress, swollen glands and toothaches (Zulueta et al. [@CR208]). The juice of the plant is also applied to treat burns and conjunctivitis (Kokwaro [@CR98]). In the Middle American Islands, the plant juice is used as a choleretic and diuretic, also to treat eye irritation, ulcers, and fever in rubella and scarlatina infections (Geissberger and Sequin [@CR69]). This plant is also known as an anti-tumor agent in Cuba and the Bahamas (Valdes and Rego [@CR185]). In India, *B. pilosa* is frequently used in traditional medicine as a remedy to treat glandular sclerosis, wounds, colds and flu, acute or chronic hepatitis, and urinary tract infections (Sundararajan et al. [@CR170]). In Taiwan, capsules, decoctions, and tinctures of the dried powder obtained from whole *B. pilosa* are customarily sold as dietary supplements or food; it is estimated that approximately 700 tons of fresh weight are consumed or marketed for diabetes treatment per year, totaling 4 million USD annually (Young et al. [@CR202]). Despite much current literature on pharmacological applications and worldwide-traditional uses, accurate scientific assessments of *B. pilosa* have been rarely provided.

Chemical composition {#Sec3}
====================

Higher plants are attractive sources of biologically active natural products. Among these, *B. pilosa* has been paid much attention due to its empirical and traditional use as a therapeutic agent and its known bioactive constituents. The phytochemical composition of *B. pilosa* includes 301 compounds that belong to the following major chemical classes: polyacetylenes (Zulueta et al. [@CR208]; Brandao et al. [@CR24]; Chang et al. [@CR31]; Redl et al. [@CR151]; Bohlmann et al. [@CR19]; Chien et al. [@CR46]), flavonoids (Ballard [@CR13]; [@CR35]; Wang et al. [@CR189]; [@CR75]), phenolic acids, terpenes (monoterpenes, sequiterpenes, diterpenes and triterpenes) (Khanh et al. [@CR96]; Zulueta et al. [@CR208]; Chiang et al. [@CR43]; Deba et al. [@CR53], [@CR54]; Priestap and Bennett [@CR147]) and pheophytins, fatty acids and phytosterols (Geissberger and Sequin [@CR69]; Chang et al. [@CR31]; Lee et al. [@CR111]; Sarg et al. [@CR156]). The major substances identified in *B. pilosa* are polyacetylenes, flavonoids, and triterpenes, and some essential oils; these are considered as the main active constituents responsible for the various pharmacological actions of the plant.

Polyacetylenes {#Sec4}
--------------

Polyacetylenes form a distinct group of chemically reactive natural products. More than 1400 different polyacetylenes and derivatives have been isolated and identified. Among these, 37 polyacetylenic compounds **1**--**37** are found in different parts of *B. pilosa* (Table [2](#Tab2){ref-type="table"}), their structural patterns show striking differences (Fig. [1](#Fig1){ref-type="fig"}). Most of the polyacetylenes identified in this plant are aliphatic acetylenes containing triple or double bonds with their cyclic, aromatic and glucoside rings or heterocyclic end groups. Among them, there are compounds **4**, **5**, and **28** that contain C~12~, C~14,~ and C~13~ aliphatic chains, respectively. In particular, the complex structures are restricted to compounds containing a single triple bond with heterocyclic moieties, such as compounds **21** and **22**. The group of Bohlmann et al. ([@CR18]) was the first reporting that *B. pilosa* contains a number of polyacetylenes, of which phenylheptatriyne (PHT) (compound **1**) and 1-phenyl-hepta-5-ene-1,3-diyne (compound **15**) are the important components of the essential oils of the flowers, leaves, shoots and roots (Priestap and Bennett [@CR147]). Other polyacetylenic compounds, such as compounds **8**, and **31**--**35** are considered as key constituents of the root (Brandao et al. [@CR24]; Sarg et al. [@CR156]; Bohlmann et al. [@CR18]; Hoffmann and Hölzl [@CR76]). Recent investigations reported several derivatives of polyacetylenes, compounds **13**--**14** (Wu et al. [@CR195]) and polyacetylenic glycosides (compounds **16**--**24**) (Chang et al. [@CR31]; Wang et al. [@CR191]), all found in the aerial plant parts as well as in the whole plant in large quantities.Table 2Polyacetylenic compounds isolated from *B. pilosa*No.Compound namePlant partsPlant originReferences1Phenylheptatriyne (1-phenylhepta-1,3,5-triyne)AP, LFEO, FL, S, RGermany, Russia, CameroonBohlmann et al. ([@CR19]), Zollo et al. ([@CR207]) and Bondarenko et al. ([@CR21])26-Phenylhexa-1,3,5-triyn-1-olAPGermanyBohlmann et al. ([@CR19])36-Phenylhexa-1,3,5-triyn-1-yl acetateAPGermanyBohlmann et al. ([@CR19])4Trideca-1,11-diene-3,5,7,9-tetrayneAPGermanyBohlmann et al. ([@CR19])5Trideca-2,12-diene-4,6,8,10-tetrayn-1-olAPGermanyBohlmann et al. ([@CR19])6Trideca-2,12-diene-4,6,8,10-tetrayn-1-yl acetateAPGermanyBohlmann et al. ([@CR19])76-Phenylhex-1-ene-3,5-diyn-1-olAPGermanyBohlmann et al. ([@CR19])81-Phenyl-1,3-diyn-5-en-7-ol-acetateWP, RBrazil, GermanyBrandao et al. ([@CR24]) and Bohlmann et al. ([@CR18])9Tridec-1-ene-3,5,7,9,11-pentayneAPGermanyBohlmann et al. ([@CR19])102-*β*-[d]{.smallcaps}-Glucopyranosyloxy-1-hydroxy-5(E)-tridecene-7,9,11-triyneAP, WPTaiwan, USAChang et al. ([@CR33]) and Ubillas et al. ([@CR182])113-*β*-[d]{.smallcaps}-Glucopyranosyloxy-1-hydroxy-6(E)-tetradecene-8,10,12-triyneAP, WPTaiwan, USA, ChinaWang et al. ([@CR191]), Chang et al. ([@CR33]) and Ubillas et al. ([@CR182])12*β*-[d]{.smallcaps}-Glucopyranosyloxy-3-hydroxy-6(E)-tetradecen-8,10,12-triyneWPCubaAlvarez et al. ([@CR7])131,2-Dihydroxytrideca-5,7,9,11-tetrayneWPTaiwanWu et al. ([@CR195])141,3-Dihydroxy-6(E)-tetradecene-8,10,12-triyneWPTaiwanWu et al. ([@CR195])151-Phenyl-hept-5t-ene-1,3-diyneWPTaiwan, ArgentinaChang et al. ([@CR31]) and Priestap and Bennett ([@CR147])167-Phenyl-hepta-4,6-diyn-1,2-diolAPChinaWang et al. ([@CR191])177-Phenyl-hepta-4,6-diyne-2-olWPTaiwanChang et al. ([@CR31])187-Phenyl-hepta-2,4,6-triyn-2-olAPChinaWang et al. ([@CR191])197-Phenyl-heptene-4,6-diyn-1-olAPChinaWang et al. ([@CR191])207-Phenyl-hepta-4,6-diyn-2-olAPChinaWang et al. ([@CR191])215-(2-Phenylethynyl)-2-thiophene methanolAPChinaWang et al. ([@CR191])225-(2-Phenylethynyl)-2-*β*-glucosylmethyl-thiopheneAPChinaWang et al. ([@CR191])23(6E,12E)-3-Oxo-tetradeca-6,12-dien-8,10-diyn-1-olAPChinaWang et al. ([@CR191])24(5E)-1,5-Tridecadiene-7,9-diyn-3,4,12-triolAPChinaWang et al. ([@CR191])252-*β*-[d]{.smallcaps}-Glucopyranosyloxy-1-hydroxytrideca-5,7,9,11-tetrayne (cytopiloyne)WPTaiwanChiang et al. ([@CR45])262-*β*-[d]{.smallcaps}-Glucopyranosyloxy-1-hydroxyltrideca-3,5,7,9,11-pentryneAPChinaZhao et al. ([@CR206])271,2-Dihydroxy-5(*E*)-tridecene-7,9,11-triyneWPTaiwanWu et al. ([@CR196])282-*O*-*β*-[d]{.smallcaps}-Glucosyltrideca-11E-en-3,5,7,9-tetrayn-1,2-diol (tetrayne)LFBrazilPereira et al. ([@CR145])29(R)-1,2-Dihydroxytrideca-3,5,7,9,11-pentayneAPFijiTobinaga et al. ([@CR176])302-*β*-[d]{.smallcaps}-Glycopyrasyloxy-1-hydroxytrideca-3,5,7,9,11-pentayneAPFijiTobinaga et al. ([@CR176])31(2E)-7-Phenylhept-2-ene-4,6-diyn-1-yl acetateRGermanyBallard ([@CR13]) and Hoffmann and Hölzl ([@CR76])32(11E)-Trideca-1,11-diene-3,5,7,9-tetrayneRGermanyBallard ([@CR13]) and Hoffmann and Hölzl ([@CR76])33(2E)-Trideca-2,12-diene-4,6,8,10-tetraynalRGermanyBallard ([@CR13]) and Hoffmann and Hölzl ([@CR76])34(2E)-Trideca-2,12-diene-4,6,8,10-tetrayn-1-olRGermanyBallard ([@CR13]) and Hoffmann and Hölzl ([@CR76])352E)-Trideca-2,12-diene-4,6,8,10-tetrayn-1-yl acetateRGermanyBallard ([@CR13]) and Hoffmann and Hölzl ([@CR76])36Trideca-3-11-diene-5-7-9-triyne-1-2-diolREgyptSarg et al. ([@CR156])37Tridec-5-ene-7,9,11-triyne-3-olREgyptSarg et al. ([@CR156]) Fig. 1The structures of the polyacetylenic compounds isolated from *B. pilosa*

Flavonoids {#Sec5}
----------

Flavonoids and their derivatives such as aglycones, aglycosides, aurones, and okanin glycosides are found in most plant parts of *B. pilosa*. Twenty flavonoid glycosides have been isolated from *B. pilosa* (Table [3](#Tab3){ref-type="table"}), of which the compounds **40**--**49** are present in the leaves of the plant (Ballard [@CR13]; Hoffmann and Hölzl [@CR75], [@CR76]; Mably et al. [@CR113]; Sashida et al. [@CR158]). The eight compounds **39**, **41**, **43**, **44,** and **50**--**53** are present in the entire plant (Chiang et al. [@CR43]; Wang et al. [@CR191]; Kusano et al. [@CR103]; Zhao et al. [@CR206]) (Table [3](#Tab3){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}).Table 3Flavonoids and its derivatives isolated from *B. pilosa*No.Compound namePlant partsPlant originReferencesFlavonoid glucosides 38AstragalinAPChinaZhao et al. ([@CR206]) 39AxillarosideWPChinaWang et al. ([@CR191]) 40Apigenin 7-*O*-glucosideLFGermanyBallard ([@CR13]) and Hoffmann and Hölzl ([@CR76]) 41RutinAP, WPJapan, ChinaWang et al. ([@CR191]), Kusano et al. ([@CR103]) and Zhao et al. ([@CR206]) 42QuercituroneAPJapanKusano et al. ([@CR103]) 43CentaureinWPTaiwanChiang et al. ([@CR43]) 44JaceinWPJapan, TaiwanChiang et al. ([@CR43]) and Kusano et al. ([@CR103]) 45Quercetin-3-*O*-α-[l]{.smallcaps}-rhamnosyl (1 → 6)-*β*-[d]{.smallcaps}-galactosideAPJapanKusano et al. ([@CR103]) 46Quercetin 3-*O*-*β*-[d]{.smallcaps}-glucopyranosideLFJapanMably et al. ([@CR113]) and Sashida et al. ([@CR158]) 47LuteosideWPChinaWang et al. ([@CR191]) 48Luteolin 7-*O*-*β*-[d]{.smallcaps}-glucopyranosideLFNot statedBallard ([@CR13]) 49Quercetin 3-*O*-glucosideLFGermanyBallard ([@CR13]) and Hoffmann and Hölzl ([@CR75]) 50Quercetin 3-*O*-*β*-[d]{.smallcaps}-galactopyranosideLFGermanyBallard ([@CR13]) and Hoffmann and Hölzl ([@CR75]) 51Quercetagetin 3,6,3′-trimethyl ether-7-*O*-*β*-glucosideWPChinaWang et al. ([@CR191]) 52Quercetagetin 3,7,3′-tri-methyl ether-6-*O*-*β*-glucosideWPChinaWang et al. ([@CR191]) 53Quercetin 3-*O*-rabinobiosideWPTaiwanChiang et al. ([@CR43]) 54Quercetin 3-*O*-rutinosideWPTaiwanChiang et al. ([@CR43]) 55Kaempferol 3-(2,3-di-*E*-*p*-coumaroyl-α-[l]{.smallcaps}-rhamnopyranosideAPVietnamVuong et al. ([@CR187])Aurons glucoside 56SulfuretinAPChinaZhao et al. ([@CR206]) 576,7,3′,4′-TetrahydroxyauroneAPChinaZhao et al. ([@CR206]) 582″,4″,6″-TriacetylmaritimeinLFGermanyHoffmann and Hölzl ([@CR78]) 594″,6″-DiacetylmartimeinLFGermanyHoffmann and Hölzl ([@CR78]) 60(Z)-7-*O*-*β*-[d]{.smallcaps}-Glucopyranosyl-6,7,3′,4′-tetrahydroxyauroneLFJapanSashida et al. ([@CR158]) 61(2Z)-2-(3,4-Dihydroxybenzylidene)-6,7-dihydroxy-1-benzofuran-3(2H)-oneLFJapanSashida et al. ([@CR158]) 62(Z)-6-*O*-(6-*O*-(6-*O*-*p*-Coumaroyl-*β*-[d]{.smallcaps}-glucopyranosyl)-6,7,3′,4′-tetrahydroxyauroneLFJapanSashida et al. ([@CR158]) 63(Z)-6-*O*-(6-*O*-Acetyl-*β*-[d]{.smallcaps}-glucopyranosyl)-6,7,3′,4′-tetrahydroxyauroneLFJapanSashida et al. ([@CR158]) 64(Z)-6-*O*-*β*-[d]{.smallcaps}-Glucopyranosyl-6,7,3′,4′-tetrahydroxy auroneLFJapanMably et al. ([@CR113]) and Sashida et al. ([@CR158]) 65(Z)-6-*O*-(3″,4″,6″-Triacetyl-*β*-[d]{.smallcaps}-glucopyranosyl)-6,7,3′,4′-tetrahydroxyauroneAPChinaWang et al. ([@CR189]) 66(Z)-6-*O*-(2″,4″,6″-Triacetyl-*β*-[d]{.smallcaps}-glucopyranosyl)-6,7,3′,4′-tetrahydroxyauroneAPChinaWang et al. ([@CR189]) 67(Z)-6-*O*-(4″,6″-Diacetyl-*β*-[d]{.smallcaps}-glucopyranosyl)-6,7,3′,4′-tetrahydroxyauroneAPChinaWang et al. ([@CR189])Okanin chalcone glycosides 68Okanin-4-methyl ether-3′,4′-di-*O*-*β*-(4″,6″,4″′,6″′-tetracetyl)-glucopyranosideAPChinaWang et al. ([@CR191]) 69Okanin 4′-*O*-*β*-[d]{.smallcaps}-(4″-acetyl-6″-*trans*-*p*-coumaroyl)-glucosideLFGermanyHoffmann and Hölzl ([@CR75]) 70Okanin 4′-*O*-*β*-[d]{.smallcaps}-(2″,4″-diacetyl-6″-*trans*-*p*-coumaroyl)-glucosideLFGermanyHoffmann and Hölzl ([@CR75]) 71Okanin 4′-*O*-*β*-[d]{.smallcaps}-(3″,4″-diacetyl-6″-*trans*-*p*-coumaroyl)-glucosideLFGermanyHoffmann and Hölzl ([@CR75]) 72α,3,2′,4′-Tetrahydroxy-2′-*O*-*β*-[d]{.smallcaps}-glucopyranosyl chalconeAPChinaZhao et al. ([@CR206]) 73Okanin 3′-*O*-*β*-[d]{.smallcaps}-glucosideLFGermanyBallard ([@CR13]) and Hoffmann and Hölzl ([@CR76]) 74Okanin 4-methyl ether 3′-*O*-*β*-[d]{.smallcaps}-glucosideLFGermanyHoffmann and Hölzl ([@CR77]) 75Okanin 4′-*O*-*β*-[d]{.smallcaps}-(4″,6″-diacetyl)-glucopyranosideAPChinaWang et al. ([@CR189]) 76Okanin 4′-*O*-*β*-[d]{.smallcaps}-(2″,4″,6″-triacetyl)-glucosideLFGermanyHoffmann and Hölzl ([@CR76]) 77Okanin 4′-*O*-*β*-[d]{.smallcaps}-(6″-*trans*-*p*-coumaroyl)-glucosideLFGermanyHoffmann and Hölzl ([@CR76]) 78Okanin 4′-*O*-*β*-[d]{.smallcaps}-glucosideLFGermanyHoffmann and Hölzl ([@CR76]) 79Okanin-4′-*O*-*β*-[d]{.smallcaps}-(3″,4″,6″-triacetyl)-glucopyranosideAPChinaWang et al. ([@CR189]) 80*iso*-Okanin 7-*O*-*β*-[d]{.smallcaps}-(2″,4″,6″-triacetyl)-glucopyranosideAPChinaWang et al. ([@CR189]) 81Okanin 4′-*O*-\[*β*-[d]{.smallcaps}-glucopyranosyl-(1 → 6)-*β*-[d]{.smallcaps}-glucopyranoside\]FLGermanyHoffmann and Hölzl ([@CR79]) 82Okanin 3′,4′-di-*O*-*β*-[d]{.smallcaps}-glucosideFLGermanyHoffmann and Hölzl ([@CR79]) 83Okanin 3′-glucosideFLGermanyHoffmann and Hölzl ([@CR79]) 84Okanin 4′-glucosideFLGermanyHoffmann and Hölzl ([@CR79]) 85Okanin 4′-*O*-*β*-[d]{.smallcaps}-(6″-*O*-acetylglucosideFLGermanyHoffmann and Hölzl ([@CR79])Other flavonoids 86ApigeninFLGermanyBallard ([@CR13]) and Hoffmann and Hölzl ([@CR76]) 87ButeinAP, LFGermanyBallard ([@CR13]), Hoffmann and Hölzl ([@CR75]) and Zhao et al. ([@CR206]) 88OkaninLFGermanyBallard ([@CR13]) and Hoffmann and Hölzl ([@CR75]) 89CentaureidinWPTaiwanChiang et al. ([@CR45]) 90Digitoflavone (Luteolin)LF, WPGermanyBallard ([@CR13]), Wang et al. ([@CR189]), Hoffmann and Hölzl ([@CR75]) and Wang et al. ([@CR191]) 91Quercetin-3,4′-dimethyl ether-7-*O*-rutinosideAPChinaWang et al. ([@CR189]) and Zhao et al. ([@CR206]) 92Quercetin-3,3′-dimethoxy-7-*O*-α-[l]{.smallcaps}-rhamnopyranosyl-(1 → 6)-*β*-[d]{.smallcaps}-glucopyranosideRBrazilBrandao et al. ([@CR25]) 93Quercetin 3,3′-dimethyl ether 7-*O*-*β*-[d]{.smallcaps} glucopyranosideRBrazilBrandao et al. ([@CR25]) 94Quercetagetin 3,6,3′-trimethyl etherWPChinaWang et al. ([@CR191]) 955-*O*-MethylhoslundinAPUgandaSarker et al. ([@CR157]) Fig. 2Flavonoid compounds isolated from *B. pilosa*

Regarding the aurone glycoside constituents, 12 compounds have been isolated from *B. pilosa*. It is worth noting that the aurone glycosides are only present in the upper parts of the plant. For instance, compounds **55**, **56**, **59**, **64**, and **66** are detected in the aerial parts of the plant (Wang et al. [@CR189]; Zhao et al. [@CR206]). Other compounds are also present in the leaves, including compounds **57**--**63** (Wang et al. [@CR189]; Mably et al. [@CR113]; Sashida et al. [@CR158]) (Table [2](#Tab2){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}). Sixteen okanin chalcone glycosides are present in the leaves, flowers and aerial parts of *B. pilosa*. (Ballard [@CR13]), with compound **72** isolated from the leaves. Subsequent experiments demonstrated the presence of compounds **68**--**82** in the leaves (Hoffmann and Hölzl [@CR75], [@CR76], [@CR77], [@CR79]; Wang et al. [@CR189], [@CR191]) (Table [2](#Tab2){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}). In addition, ten flavonoids have been isolated from different parts of this plant, of which 7 have the basic skeleton structure of quercetin, such as compounds **83**, **86**--**91**, found in the whole plant. Compounds **84**--**85** have okanin structures and differ from the structure of compound **92**, a constituent detected in the leaves and aerial parts (Ballard [@CR13]; Wang et al. [@CR189]; Hoffmann and Hölzl [@CR75], [@CR76]; Wang et al. [@CR191]; Zhao et al. [@CR206]; Brandao et al. [@CR25]; Chiang et al. [@CR45]) (Table [2](#Tab2){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}).

Phenolics {#Sec6}
---------

Among the phenolics, 33 compounds **93**--**125** have been found in various parts of *B. pilosa*. Some common phenolic acids, including compounds **94**--**95**, **105**--**106**, **114**, **117** and **121**, are present in the leaves, stems, and roots (Deba et al. [@CR54]; Sarker et al. [@CR157]) (Table [4](#Tab4){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"}). Twelve caffeoylquinic acids and derivatives of *p*-coumaric acid, namely compounds **96**--**101**, **108**--**110**, and **123**--**125** have also been isolated from the whole *B. pilosa* plant. Both Sashida et al. ([@CR158]) and Ogawa and Sashida ([@CR139]) reported the presence of 5 derivatives of caffeoylquinic acid (compounds **108**--**110**, and **125**) and 2 derivatives of *p*-coumaric acid (compounds **123** and **124**) in the leaves. Other caffeoylquinic acids (compounds **96--101**) have been found in the whole plant (Wang et al. [@CR189]; Chiang et al. [@CR43]; Kusano et al. [@CR103]; Kumar and Sinha [@CR100]) (Table [2](#Tab2){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}).Table 4The phenolic compounds isolated from *B. pilosa*No.Compound namePlant partsPlant originReferences96Benzoic acidAPUgandaSarker et al. ([@CR157])97Caffeic acidLF, S, RJapanDeba et al. ([@CR53])98Chlorogenic acidWPJapan, TaiwanChiang et al. ([@CR43]) and Kusano et al. ([@CR103])993,4-di-*O*-Caffeoylquinic acidAP, WPJapan, TaiwanChiang et al. ([@CR43]) and Kusano et al. ([@CR103])1003,5-di-*O*-Caffeoylquinic acidAP, WPJapan, TaiwanChiang et al. ([@CR43]) and Kusano et al. ([@CR103])1014,5-di-*O*-Caffeoylquinic acidAP, WPJapan, TaiwanChiang et al. ([@CR43]) and Kusano et al. ([@CR103])102Neochlorogenic acidAPJapanKusano et al. ([@CR103])1034-*O*-Caffeoylquinic acidAPJapanKusano et al. ([@CR103])104DimethoxyphenolRJapanDeba et al. ([@CR53])105EugenolLF, RJapanDeba et al. ([@CR53])106Ethyl caffeateWPTaiwanChiang et al. ([@CR44])107Ferulic acidLF, S, RJapanDeba et al. ([@CR53])108Gallic acidAPCubaAbajo et al. ([@CR1])109*iso*-VanillinLFJapanDeba et al. ([@CR53])1102-*O*-Caffeoyl-2-C-methyl-[d]{.smallcaps}-erythronic acidLFJapanOgawa and Sashida ([@CR139])111Methyl 2-*O*-caffeoyl-2-C-Methyl-[d]{.smallcaps}-erythronic acidLFJapanOgawa and Sashida ([@CR139])112Methyl 3-*O*-caffeoyl-2-C-Methyl-[d]{.smallcaps}-erythronic acidLFJapanOgawa and Sashida ([@CR139])113*p*-Coumaric acidLF, S, RGermany, JapanDeba et al. ([@CR53]) and Hoffmann and Hölzl ([@CR78])114PyrocatechinLF, S, RJapanDeba et al. ([@CR53])115*p*-Hydroxybenzoic acidLF, S, RJapanDeba et al. ([@CR53])116Protocatechuic acidLF, S, RJapanDeba et al. ([@CR53])117*p*-VinylguaiacolLF, S, RJapanDeba et al. ([@CR53])118Salicylic acidR, SJapanDeba et al. ([@CR53])119Tannic acidAPNot statedAyyanar and Ignacimuthu ([@CR12])120Vanillic acidRUganda, JapanDeba et al. ([@CR53]) and Sarker et al. ([@CR157])1212-Phenyl-ethanolWPTaiwanChang et al. ([@CR31])1222-Hydroxy-6-methylbenzaldehydeLF, S, RJapanDeba et al. ([@CR53])1234-Ethyl-1,2-benzenediolLF, S, RJapanDeba et al. ([@CR53])1244-*O*-(6-*O*-*p*-Coumaroyl-*β*-[d]{.smallcaps}-glucopyranosyl)-*p*-coumaric acidLFJapanSashida et al. ([@CR158])1254-*O*-(2-*O*-Acetyl-6-*O*-*p*-coumaroyl-*β*-[d]{.smallcaps}-glucopyranosyl)-*p*-coumaric acidLFJapan, ChinaWang et al. ([@CR189]) and Sashida et al. ([@CR158])1263-*O*-Caffeoyl-2-C-methyl-[d]{.smallcaps}-erythrono-1,4-lactoneLFJapanOgawa and Sashida ([@CR139]) Fig. 3The structures of phenolic compounds identified from *B. pilosa*

Overall, there are 99 terpene compounds (monoterpenes, sesquiterpenes, diterpenes, triterpenes, and tetraterpenes) that have been found in *B. pilosa* (Table [5](#Tab5){ref-type="table"}). Their chemical structures (compounds **126**--**224** and **225**--**262)** are shown in Fig. [4](#Fig4){ref-type="fig"}. Among them, there are 28 monoterpenes (C~10~), 58 sesquiterpenes (C~15~), 6 diterpenes (C~20~), and 6 triterpenes (C~25~), while the others represent different types of terpenoid derivatives. They contain both hydrocarbons and oxygenated compounds (Fig. [4](#Fig4){ref-type="fig"}). Among the monoterpenes, both acyclic monoterpenes such as compounds **127**, **129**, **144**, and **147** and monocylic monoterpenes such as compounds **131**, **135**, **139** comprise 8 compounds. Bicyclic compounds **130**, **139**, **149**, and **152** have also been identified (Deba et al. [@CR54]; Priestap and Bennett [@CR147]; Zollo et al. [@CR207]; Ogunbinu et al. [@CR140]). Most sesquiterpenes are monocyclic, bicyclic, or tricyclic, with the exception of the two compounds **167** and **209** (Deba et al. [@CR53]; Priestap and Bennett [@CR147]; Zollo et al. [@CR207]) which are linear sesquiterpenes. The individual structures of sesquiterpenes show substantial differences (Fig. [4](#Fig4){ref-type="fig"}). Most compounds, the monoterpenes and sesquiterpenes, are found in the essential oils obtained from various parts of *B. pilosa* (Table [6](#Tab6){ref-type="table"}; Fig. [4](#Fig4){ref-type="fig"}). The acyclic diterpenes of compounds **213**--**215** and **217** were obtained from the whole *B. pilosa* plant. Two tricylic diterpenenes, namely the compounds **212** and **216** (Zulueta et al. [@CR208]; Deba et al. [@CR53]; Priestap and Bennett [@CR147]; Zollo et al. [@CR207]) are constituents of the essential oils derived from the shoots (Table [6](#Tab6){ref-type="table"}; Fig. [4](#Fig4){ref-type="fig"}). Pentacyclic polyterpenes (triterpenes) compounds **218**--**220** and **223** and the one acyclic polyterpene compound **222** have also been detected in whole plants (Geissberger and Sequin [@CR69]; Chang et al. [@CR31]; Sarg et al. [@CR156]; Chen et al. [@CR40]). However, the only compound found in the leaf was tetraterpene, compound **224**.Table 5Terpenes identified from *B. pilosa*No.Compound namePlant partsPlant originReferencesMonoterpenes 127CampheneLF, FL (EO)Cameroon, JapanDeba et al. [@CR54]) and Zollo et al. [@CR207]) 128(E)-*β*-OcimeneLF (EO)CameroonZollo et al. ([@CR207]) 129*m*-CymolLF, FL (EO)JapanDeba et al. ([@CR54]) 130Myrcene, *β*-MyrceneLF, FL, S, R (EO)Cameroon, ArgentinaPriestap and Bennett ([@CR147]) and Zollo et al. ([@CR207]) 131Limoneneroots, R (EO)ArgentinaPriestap and Bennett ([@CR147]) 132PerilleneFL, S (EO)ArgentinaPriestap and Bennett ([@CR147]) 133SabineneLF, S, R (EO)Cameroon, ArgentinaPriestap and Bennett ([@CR147]) and Zollo et al. ([@CR207]) 134*trans*-PinocarveolS (EO)NigeriaOgunbinu et al. ([@CR140]) 135TerpinoleneLF (EO)CameroonZollo et al. ([@CR207]) 136(Z)-*β*-OcimeneLF, FL (EO)Cameroon, ArgentinaPriestap and Bennett ([@CR147]) and Zollo et al. ([@CR207]) 137*γ*-TerpineneLF, FL (EO)Cameroon, JapanDeba et al. ([@CR54]) and Zollo et al. ([@CR207]) 138α-PineneLF, FL, S, R (EO)Argentina, JapanDeba et al. ([@CR54]) and Priestap and Bennett ([@CR147])) 139α-PhellandreneLF, FL (EO)Cameroon, JapanDeba et al. ([@CR54]) and Zollo et al. ([@CR207]) 140*β*-PineneLF, FL, S (EO)Cameroon, ArgentinaPriestap and Bennett ([@CR147]) and Zollo et al. ([@CR207]) 141*β*-PhellandreneLF, FL, S, R (EO)ArgentinaPriestap and Bennett ([@CR147]) 142*β*-*trans*-OcimeneLF, FL (EO)JapanDeba et al. ([@CR54]) 143*β*-*cis*-OcimeneLF, FL (EO)JapanDeba et al. ([@CR54]) 1443-CareneFL (EO)JapanDeba et al. ([@CR54]) 145(4E,6Z)-2,6-Dimethyl-2,4,6-octatrieneFL, LF (EO)Argentina, JapanDeba et al. ([@CR54]) and Priestap and Bennett ([@CR147]) 146BorneolR (EO)ArgentinaPriestap and Bennett ([@CR147]) 147*cis*-VerbenolLF, FL (EO)JapanDeba et al. ([@CR54]) 148Linalool*, β*-LinaloolLF, S, FL (EO)Cameroon, ArgentinaDeba et al. ([@CR54]), Priestap and Bennett ([@CR147]) and Zollo et al. ([@CR207]) 149*p*-Cymen-8-olLF, FL(EO)JapanDeba et al. ([@CR54]) 150Terpinen-4-olLF (EO)JapanZollo et al. ([@CR207]) 151*Trans*-VerbenolFL (EO)JapanDeba et al. ([@CR54]) 152α-TerpineolLF, S, R (EO)Cameroon, ArgentinaPriestap and Bennett ([@CR147]) and Zollo et al. ([@CR207]) 1531,8-CineoleLF (EO)CameroonZollo et al. ([@CR207]) 1544-TerpineolLF, FL (EO)JapanDeba et al. ([@CR54])Sesquiterpenes 155Acorenone BLF (EO)NigeriaOgunbinu et al. ([@CR140]) 156*allo*-AromadendreneS (EO)NigeriaOgunbinu et al. ([@CR140]) 157BicyclogermacreneLF, SBrazilGuaratini et al. ([@CR72]) 158*E*-caryophilleneLFBrazilGuaratini et al. ([@CR72]) 159(+)-Epi-bicyclosesquiphellandreneFL, LF (EO)Argentina, JapanDeba et al. ([@CR54]) and Priestap and Bennett ([@CR147]) 160Cedr-8(15)-en-9α-olLF (EO)NigeriaOgunbinu et al. ([@CR140]) 161*cis*-Calamenen-10-olS (EO)NigeriaOgunbinu et al. ([@CR140]) 162CyclosativeneLF, S (EO)NigeriaOgunbinu et al. ([@CR140]) 163DauceneLF (EO)NigeriaOgunbinu et al. ([@CR140]) 164epi-10-γ-EudesmolS (EO)NigeriaOgunbinu et al. ([@CR140]) 165epi-LongipinanolL (EO)NigeriaOgunbinu et al. ([@CR140]) 166Epoxy alloaromadendreneS (EO)NigeriaOgunbinu et al. ([@CR140]) 167ElixeneLF, FL (EO)JapanDeba et al. ([@CR54]) 168Farnesene, (E)-*β*-FarneseneLF, FL (EO)Cameroon, JapanDeba et al. ([@CR54]) and Zollo et al. ([@CR207]) 169Germacrene ALF, S (EO)NigeriaOgunbinu et al. ([@CR140]) 170Germacrene-DLF, FL, S (EO)CameroonZollo et al. ([@CR207]) 171Humulene oxide IILF, S (EO)NigeriaOgunbinu et al. ([@CR140]) 172Intermedeol \<neo\>S (EO)NigeriaOgunbinu et al. ([@CR140]) 173IsoledeneLF, FL (EO)JapanDeba et al. ([@CR54]) 174Selina-3,11-dien-6α-olLF (EO)NigeriaOgunbinu et al. ([@CR140]) 175Selina-3,7(11)-dieneLFBrazilGuaratini et al. ([@CR72]) 176*trans*-Calamenen-10-olLF, S (EO)NigeriaOgunbinu et al. ([@CR140]) 177*trans*-α-BergamoteneLF (EO)NigeriaOgunbinu et al. ([@CR140]) 178ValenceneS (EO)NigeriaOgunbinu et al. ([@CR140]) 179Z-γ-BisaboleneLFBrazilGuaratini et al. ([@CR72]) 180*β*-CedreneS (EO)NigeriaOgunbinu et al. ([@CR140]) 181*β*-SelineneLF (EO)NigeriaOgunbinu et al. ([@CR140]) 182α-CadinolLF, FL, S (EO)Cameroon, ArgentinaPriestap and Bennett ([@CR147]) and Zollo et al. ([@CR207]) 183α-CalacoreneLF (EO)NigeriaOgunbinu et al. ([@CR140]) 184α-BergamoteneLF, FL (EO)JapanDeba et al. ([@CR54]) 185α-CopaeneLF, FL, S, R (EO)Cameroon, ArgentinaPriestap and Bennett ([@CR147]) and Zollo et al. ([@CR207]) 186α-CaryophylleneLF, FL (EO)JapanDeba et al. ([@CR54]) 187α-CubebeneLF, FL, R (EO)Cameroon, JapanDeba et al. ([@CR54]) and Priestap and Bennett ([@CR147]) 188α-GurjuneneLF (EO)NigeriaOgunbinu et al. ([@CR140]) 189α-HumuleneLF, FL, R (EO)Cameroon, ArgentinaPriestap and Bennett ([@CR147]) and Zollo et al. ([@CR207]) 190α-MuuroleneLFBrazilGuaratini et al. ([@CR72]) 191α-YlangeneLF, FL (EO)Cameroon, JapanDeba et al. ([@CR54]) and Zollo et al. ([@CR207]) 192*β*-BourboneneLF, FL (EO)JapanDeba et al. ([@CR54]) 193*β*-BisaboleneLF, FL (EO)JapanDeba et al. ([@CR54]) 194*β*-CaryophylleneLF, FL, S, R (EO)Cameroon, ArgentinaPriestap and Bennett ([@CR147]) and Zollo et al. ([@CR207]) 195*β*-CubebeneLF, FL (EO)JapanDeba et al. ([@CR54]) 196(−)-*β*-CadieneLF, FL (EO)JapanDeba et al. ([@CR54]) 197*β*-ElemeneLF, S, R (EO)Cameroon, ArgentinaPriestap and Bennett ([@CR147]) and Zollo et al. ([@CR207]) 198*β*-GurjuneneLF, FLBrazilGuaratini et al. ([@CR72]) 199γ-CadineneLF (EO)CameroonZollo et al. ([@CR207]) 200γ-MuuroleneS (EO)NigeriaOgunbinu et al. ([@CR140]) 201τ-MuuroleneLF, FL (EO)JapanDeba et al. ([@CR54]) 202τ-CadinolLF (EO)NigeriaOgunbinu et al. ([@CR140]) 203τ-CadineneLF, FL (EO)JapanDeba et al. ([@CR54]) 204δ-ElemeneWP (EO)ArgentinaPriestap and Bennett ([@CR147]) 205δ-CadineneLF, FL, S (EO)Cameroon, ArgentinaPriestap and Bennett ([@CR147]) and Zollo et al. ([@CR207]) 2061-epi-CubenolLF (EO)NigeriaOgunbinu et al. ([@CR140]) 20714-Oxy-α-muuroleneLF (EO)NigeriaOgunbinu et al. ([@CR140]) 20814-Hydroxy-δ−cadineneLF (EO)NigeriaOgunbinu et al. ([@CR140]) 209Caryophyllene oxideLF, FL, S (EO)JapanDeba et al. ([@CR54]) and Priestap and Bennett ([@CR147]) 210Epi-cedrolR (EO)ArgentinaPriestap and Bennett ([@CR147]) 211(E)-nerolidol; trans-Nerolidol)LF, FL (EO)ArgentinaPriestap and Bennett ([@CR147]) 212Precocene 1LF (EO)CameroonZollo et al. ([@CR207]) 213SpathulenolLF, S, R (EO)Cameroon, ArgentinaPriestap and Bennett ([@CR147]) and Zollo et al. ([@CR207]) 214T-MuurololLF (EO)CameroonZollo et al. ([@CR207])Diterpenes 215PimaradieneS (EO)ArgentinaPriestap and Bennett ([@CR147]) 216Phytyl heptanoateLFNot statedZulueta et al. ([@CR208]) 217PhytolWPChinaChang et al. ([@CR31]) 218Phytenic acidWPChinaChang et al. ([@CR31]) 219Sandaracopimara-8(14),15-dieneS (EO)NigeriaOgunbinu et al. ([@CR140]) 2201-EicoseneLF, S (EO)NigeriaOgunbinu et al. ([@CR140])Triterpenes 221FriedelinLF, S, FL, SDChina, TanzaniaGeissberger and Sequin ([@CR69]) and Chen et al. ([@CR40]) 222Friedelan-3 *β*-olLF, S, FL, SDChina, TanzaniaGeissberger and Sequin ([@CR69]) and Chen et al. ([@CR40]) 223LupeolPPEgyptSarg et al. ([@CR156]) 224Lupeol acetatePPEgyptSarg et al. ([@CR156]) 225SqualeneWPChinaChang et al. ([@CR31])226*β*-AmyrinPPEgyptSarg et al. ([@CR156])Tetraterpene 227*Β*-CaroteneLeafZimbabweBenhura and Chitsiku ([@CR15]) Fig. 4Structures of terpenes identified from *B. pilosa* Table 6Other compounds found in the essential oils of *B. pilosa*Structure no.Compound namePlant partsPlant originReferences228Ac*et al* (1,1-Diethoxyac*et al*)LF, FL (EO)JapanDeba et al. ([@CR54])229Bornyl acetateWP (EO)ArgentinaDeba et al. ([@CR54]) and Priestap and Bennett ([@CR147])230Caryophylla-4(14),8(15)-dien-5-olLF (EO)NigeriaOgunbinu et al. ([@CR140])231*cis*-3-Hexen-1-olLF (EO)JapanDeba et al. ([@CR54])232*cis*-3-Hexenyl acetateLF (EO)JapanDeba et al. ([@CR54])233*cis*-Chrysanthenyl acetateR (EO)ArgentinaPriestap and Bennett ([@CR147])234DiphenylenemethaneLF, FL (EO)JapanDeba et al. ([@CR54])235(E)-Geranyl acetoneLF (EO)NigeriaOgunbinu et al. ([@CR140])236HexadecanolLF, S, R (EO)ArgentinaPriestap and Bennett ([@CR147])237HexahydrofarnesylacetoneLF, S (EO)NigeriaOgunbinu et al. ([@CR140])238Hexadecyl acetateR (EO)ArgentinaPriestap and Bennett ([@CR147])239IsophoroneLF, S (EO)NigeriaOgunbinu et al. ([@CR140])240MegastigmatrienoneLF, FL (EO)JapanDeba et al. ([@CR54])241MesityleneLF (EO)NigeriaOgunbinu et al. ([@CR140])242Methyl hexadecanoateLF (EO)NigeriaOgunbinu et al. ([@CR140])243Methyl linoleateLF (EO)NigeriaOgunbinu et al. ([@CR140])244Muurol-5-en-4-one \<*cis*-14-nor\>LF, S (EO)NigeriaOgunbinu et al. ([@CR140])245n-TricosaneS (EO)NigeriaOgunbinu et al. ([@CR140])246n-DecaneLF (EO)NigeriaOgunbinu et al. ([@CR140])247n-DodecaneLF, S (EO)NigeriaOgunbinu et al. ([@CR140])248n-DocosaneS (EO)NigeriaOgunbinu et al. ([@CR140])249n-TetradecaneS (EO)NigeriaOgunbinu et al. ([@CR140])250n-HexadecaneS (EO)NigeriaOgunbinu et al. ([@CR140])251n-HeptadecaneS (EO)NigeriaOgunbinu et al. ([@CR140])252n-HeneicosaneS (EO)NigeriaOgunbinu et al. ([@CR140])253n-OctadecaneLF (EO)NigeriaOgunbinu et al. ([@CR140])254*n*-PentadecaneShoot (EO)NigeriaOgunbinu et al. ([@CR140])255PentadecanalLeaf, shoot (EO)NigeriaOgunbinu et al. ([@CR140])256OctadecadienolS,R (EO)Priestap and Bennett ([@CR147])257NonanalLF (EO)NigeriaOgunbinu et al. ([@CR140])258Phenyl ac*et al*dehydeS (EO)NigeriaOgunbinu et al. ([@CR140])259PseudocumeneS (EO)NigeriaOgunbinu et al. ([@CR140])2601-HeptadeceneS (EO)NigeriaOgunbinu et al. ([@CR140])2611-OctadeceneLF (EO)NigeriaOgunbinu et al. ([@CR140])2622,5,9-Trimethylcycloundeca-4,8 dienoneFL, LF (EO)ArgentinaDeba et al. ([@CR54]) and Priestap and Bennett ([@CR147])2636-Methyl-5-hepten-2-oneLF, S (EO)NigeriaOgunbinu et al. ([@CR140])264DecanalS (EO)NigeriaOgunbinu et al. ([@CR140])265TridecaneLF, S (EO)NigeriaOgunbinu et al. ([@CR140])

With compounds **225**--**262**, there are 38 terpene derivatives, present in *B. pilosa* (Table [6](#Tab6){ref-type="table"}; Fig. [5](#Fig5){ref-type="fig"}). Three C~6~ acyclic (compounds **225**, **228**, and **229**), and 22 C~8~, C~9~, C~12~, C~14~, C~16~, C~17~, C~18~, C~19~, C~21~, and C~22~ acyclic compounds, including compounds **230**, **234**, **239**, **240**, **246**, **249**, **247**, **245**, **254**, and **260**, respectively, were identified (Deba et al. [@CR53], [@CR54]; Priestap and Bennett [@CR147]; Ogunbinu et al. [@CR140]). These substances are present in the oils of leaves, shoots, roots and flowers. The other compounds are monocyclic and tricyclic terpenes and several other unique structures (Table [6](#Tab6){ref-type="table"}).Fig. 5Other structures of compounds identified in the essential oils of different parts of *B. pilosa*

Pheophytins, fatty acids and phytosterols {#Sec7}
-----------------------------------------

Eight pheophytins, compounds **263**--**270**, have been isolated from the leaves of *B. pilosa* (Lee et al. [@CR111]). Two novel pheophytins, compounds **264** and **265** containing two rare four-membered peroxides were also identified. Other identified compounds **263**, **266,** and **270** also were identified (Fig. [6](#Fig6){ref-type="fig"}). A total of 12 long-chain fatty acids (compounds **271**--**282**) are present in *B. pilosa*. Some of these fatty acids, such as compounds **278**--**282**, have been detected in the essential oils of the leaves. Other fatty acid derivatives (compounds **272**--**274**) have been isolated from whole plants (Table [7](#Tab7){ref-type="table"}; Fig. [6](#Fig6){ref-type="fig"}) (Zulueta et al. [@CR208]; Geissberger and Sequin [@CR69]; Chang et al. [@CR31]; Sarg et al. [@CR156]). To date, six phytosterols and phytosterol derivatives corresponding to the compounds **283**--**288** have been isolated from the whole plant (Geissberger and Sequin [@CR69]; Chang et al. [@CR31]; Sarg et al. [@CR156]). Other compounds, including derivatives of alkanes, alkaloids, acetylacetone, dicarboxylic acids, glycol ethers, tocopherols and thiophenes (compounds **289**--**296**) are available in the whole plant (Taylor [@CR173]; Sarg et al. [@CR156]; Ayyanar and Ignacimuthu [@CR12]) (Table [7](#Tab7){ref-type="table"}; Fig. [6](#Fig6){ref-type="fig"}).Fig. 6The structures of pheophytins, fatty acids, phytosterols and miscellaneous compounds isolated from *B. pilosa* Table 7Pheophytins, fatty acids, phytosterols and other compounds isolated from *B. pilosa*No.Compound namePlant partsPlant originReferencesPheophytins 266Aristophyll-CLFTaiwanLee et al. ([@CR111]) 267Bidenphytins ALFTaiwanLee et al. ([@CR111]) 268Bidenphytins BLFTaiwanLee et al. ([@CR111]) 269Pheophytin aLFTaiwanLee et al. ([@CR111]) 270(13^2^R)-13^2^-Hydroxypheophytin aLFTaiwanLee et al. ([@CR111]) 271(13^2^S)-13^2^-Hydroxypheophytin aLFTaiwanLee et al. ([@CR111]) 272(13^2^R)-13^2^-Hydroxypheophytin bLFTaiwanLee et al. ([@CR111]) 273(13^2^S)-13^2^-Hydroxypheophytin bLFTaiwanLee et al. ([@CR111])Fatty acids 274Behenic acidLFNot statedZulueta et al. ([@CR208]) 2752-Butoxyethyl linoleateWPTaiwanChang et al. ([@CR31]) 276Ethyl linoleate acidWPTaiwanChang et al. ([@CR31]) 277Methyl linolenateWPTaiwanChang et al. ([@CR31]) 278Linolenic acidWPTaiwanChang et al. ([@CR31]) 279Capric acidPPEgyptSarg et al. ([@CR156]) 280Elaidic acidLFNot statedZulueta et al. ([@CR208]) 281Myristic acidPPEgyptSarg et al. ([@CR156]) 282Lauric acidPPEgyptSarg et al. ([@CR156]) 283Linoleic acidLF, S, FL, SD, WPTanzania, ChinaGeissberger and Sequin ([@CR69]) and Chang et al. ([@CR31]) 284Palmitic acidPPEgyptSarg et al. ([@CR156]) 285Palmitoleic acidPPEgyptSarg et al. ([@CR156])Phytosterols 286CampestrolLF, S, FL, SDTanzaniaGeissberger and Sequin ([@CR69]) 287DaucosterolPPEgyptSarg et al. ([@CR156]) 288StigmasterolLF, S, FL, SD, WPTanzaniaGeissberger and Sequin ([@CR69]) and Chang et al. ([@CR31]) 289*β*-SitosterolLF, S, FL, SD,TanzaniaGeissberger and Sequin ([@CR69]) 2905α-Stigmasta-7-en-3 *β*-olWPChinaChang et al. ([@CR31]) 2915α-Stigmasta-7,22t-dien-3 *β*-olWPChinaChang et al. ([@CR31])Miscellaneous Coumarin  292AesculetinPPEgyptSarg et al. ([@CR156]) Alkane  293Heptanyl 2-*O*-*β*-xylofuranosyl-(1 → 6)-*β*gluco pyranosideWPTaiwanChiang et al. ([@CR43]) Alkaloid  294CaffeineAPEgypt, ugandaSarker et al. ([@CR157]) Acetylacetone  2953-Propyl-3-(2,4,5-trimethoxy)benzyloxy-pentan-2,4-dioneLFIndiaKumar and Sinha ([@CR100]) Chromene  296Precocene 1LF (EO)CameroonZollo et al. ([@CR207]) Dicarboxylic  297(E)-Butenedioic acidAPChinaZhao et al. ([@CR206])  298Butanedioic acidAPRussia, ChinaWang et al. ([@CR189]) and Bondarenko et al. ([@CR22]) Glycol ethers  2992-Butoxy ethanolWPTaiwanChang et al. ([@CR31]) Tocopherol  300α-Tocopheryl quinoneWPTaiwanChang et al. ([@CR31]) Thiophen  3011-(Thiophen-2-yl)-ethanoneAPGermanyBohlmann et al. ([@CR18])*LF* leaf, *FL* flower, *S* shoot, *R* root, *SD* seed, *WP* whole plant, *AP* aerial part, *PP* plant powder

Biological activities {#Sec8}
=====================

Great efforts have been made in the search for new therapeutic agents since the 1950s, which led to some clinical studies with *B. pilosa* as medicinal plant.

Malaria {#Sec9}
-------

Among the Asteraceae species, *B. pilosa* is one of the most promising and potent anti-malaria botanicals, as it shows strong inhibition against parasitemia in in vitro cultures (Connelly [@CR50]; Brandao et al. [@CR24]). In earlier reports, Spencer et al. ([@CR166]) and N'Dounga et al. ([@CR131]) demonstrated that the plant has low in vitro activities against *Plasmodium berghei*. More importantly, dried whole plant materials of *B. pilosa* extracted with ethanol, butanol, and chloroform, show a 90 % inhibition against the in vitro growth of the deadly malarial strain *Plasmodium falciparum* at 50 µg/ml (Brandao et al. [@CR24]; Krettli et al. [@CR99]). The ethanolic extract of the root exhibits a much higher inhibition in mice infected with P*lasmodium berghei* than the whole plant, leaf and stem extracts (Andrade-Neto et al. [@CR9]). The chloroform fractions of the root exert an 86 % suppression of *Plasmodium falciparum* growth in vitro. Another trial in mice confirmed this effect in vivo, with a reduction in parasitemia of up to 60 % in mice infected with *Plasmodium berghei* at 250--500 mg/kg (Andrade-Neto et al. [@CR9]). Chloroquine- or mefloquine-resistant *Plasmodium falciparum* strains are susceptible to *B. pilosa* (IC~50~ = 10.4--49.8 µg/mL) in vitro. Interestingly, extracts from plants cultivated under standardized conditions are less active in comparison with wild plants (Andrade-Neto et al. [@CR9]; Kaur et al. [@CR94]). *Plasmodium falciparm* (NF54 strain) in human blood is significantly inhibited at IC~50~ = 32.8 µg/mL using the hexane extract of *B. pilosa* leaves in in vivo assays (Kumari et al. [@CR101]). The chloroform, ether and ether methanol (1:1) fractions obtained from the root extract provide both a polyacetylenic ingredient, compound **8** (Brandao et al. [@CR24]; Bohlmann et al. [@CR18]; Oliveira et al. [@CR141]) and 2 methoxylated flavonoids as the major compounds **89** and **90** (Brandao et al. [@CR25]). These show strong anti-malarial activities in vivo (Krettli et al. [@CR99]; Andrade-Neto et al. [@CR9]; Oliveira et al. [@CR141]) and are bioactive towards *Plasmodium* (Young et al. [@CR202]; Oliveira et al. [@CR141]).

The strong anti-malarial ability of *B. pilosa* is likely due to its abundant production of polyacetylenes and flavonoids. For instance, compound **1** is one of the major polyacetylenic compounds occurring at high concentrations, which is bioactive towards several malarial strains (N'Douga et al. [@CR131]) and shows potent inhibitory activity against *Plasmodium falciparum,* with IC~50~ = 6.1 µg/mL (Kumari et al. [@CR101]). However, *B. pilosa* likely has low activities because the active compounds are rapidly degraded during fractionation or at storage. The biological activities of the polyacetylenes are dependent on light for their toxicity and ultraviolet light for the expression of their activities (Brandao et al. [@CR24]; Kagan [@CR90]).

Another polyacetylenic constituent is compound **29** (Tobinaga et al. [@CR176]) contained in the aerial parts of the plant, which also exhibits complete in vitro inhibition of *P. falciparum* at 1 µg/mL and causes significant suppression of the *Plasmodium berghei* strain at 0.8 mg/kg in infected mice over 4 days (Tobinaga et al. [@CR176]). This compound is stable in the organic solvents methanol or ethyl acetate, but unstable in the solid state (Tobinaga et al. [@CR176]; Cambie and Ash [@CR28]). Compound **286** is present in all parts of *B. pilosa* and is very active in mice infected by *Plasmodium berghei* at a dose of 15 mg/kg, inhibiting parasitemia by up to 58 % at 8 days after parasite inoculation (Uchoa et al. [@CR183]). However, this high dose raises the question of its practical relevance. Interestingly, compound **84**, contained in the aerial parts of the plant (Ballard [@CR13]; Hoffmann and Hölzl [@CR76]) is inhibitory also for leishmania (Nielsen et al. [@CR136]). This suggests that this compound should be further investigated for the development of new anti-malarial and anti-leishmania drugs in the future. *B. pilosa* has potential beneficial therapeutic actions that can be used in the management of malaria and possibly even of leishmania.

Microbial infections {#Sec10}
--------------------

Many studies have reported that *B. pilosa* has strong anti-microbial activities, including anti-viral activities against type I and II herpes simplex viruses (HSV). Hot water extracts of dried *B. pilosa* at 100 µg/ml display significant inhibition of the replication of HSV (11.9 % for HVS-1, p \< 0.01; 19.2 % for HVS-2, p \< 0.005). Further, in vitro experiments with acyclovir indicate that the application of 500 µg/ml of the extract inhibits HSV2 by 33 %, while the effect on HSV1 is 39.02 %, and that of acyclovir is 45.07 %. The suppressive effects on HSV are dose-dependent, with *B. pilosa* being more effective against HSV2 and less potent compared to acyclovir (Chiang et al. [@CR42]). Ashafa and Afolayan ([@CR11]) reported that the MeOH and Me~2~CO extracts of the subaerial parts of *B. pilosa* remarkably suppress all Gram-positive and Gram-negative bacteria at 5 to 10 mg/ml and also completely retard the growth of *Penicilium notatum* at 0.1 mg/ml (Ashafa and Afolayan [@CR11]).

Furthermore, both the petroleum ether and the MeOH/H~2~O extracts of dried leaves and aerial parts of *B. pilosa* display potent anti-bacterial activities, mainly against Gram-positive bacteria (Geissberger and Sequin [@CR69]; Rabe and Van Staden [@CR148]). In vitro experiments also indicated that the water/ethanol extracts (95 %) of the dried powder of the leaves and stems of *B. pilosa* are active against several bacterial strains, including *Bacillus cereus*, *Escherichia coli*, and *Staphylococcus aureus*; they are more potent than gentamycin sulfate (Rojas et al. [@CR153]). Notably, at concentration of 100 µg/ml, these extracts show suppressive effects towards *Mycobacterium intracellulare* (Van Puyvelde et al. [@CR186]). The petrol, dichloromethane, and EtOAc fractions of the dried plant also significantly inhibit the growth of several other microorganisms (Khan et al. [@CR95]). Aqueous extracts and essential oils of the leaves and flowers of *B. pilosa* significantly reduce the growth of six bacteria and three fungal strains (Deba et al. [@CR54]). The suppressive effect of the flower essential oil is higher for Gram-negative than Gram-positive bacteria. The anti-microbial activity of *B. pilosa* is likely due to appreciable amounts of some monoterpenes and sesquiterpenes, such as compounds **193**, **207**, and **147**. These compounds have a wide range of anti-microbial properties, as reported in earlier studies (Magiatis et al. [@CR115]; Pattnaik et al. [@CR144]). Several other monoterpenes, such as compounds **137** and **130**, are known for their anti-bacterial effects (Magiatis et al. [@CR115]; Sokmen et al. [@CR165]).

Since compound **1** is found in *B. pilosa*, its biological activity against various microorganisms has been examined. Preliminary investigations of the anti-microbial activity of **1** were conducted by Bondarenko et al. ([@CR20]) and Wat et al. ([@CR192]) in studies that demonstrated that compound **1** is a growth inhibitor of a wide variety of microorganisms, including bacteria, fungi, yeast, and molds (Kagan [@CR90]; Bondarenko et al. [@CR21]; Bondarenko et al. [@CR22]). However, these studies neglect to evaluate the activity levels of PHT towards the tested microorganisms in the presence of light. In another study, compound **1** was found to photosensitize the cereal pathogen *F.* *culmorun* and to suppress the germination and growth of its *macroconidia* and *mycelia* (Bourque et al. [@CR23]). This interesting compound has anthelminthic and protozoacidal activity in vitro in infected mice and inhibits *E. coli* and *S. cerevisiae* in a light--dependent manner. Towers and Wat ([@CR178]) demonstrated that compound **1** has no activity in the dark against bacteria, yeast, and filamentous fungi, but that efficacy could be induced with fluorescent lamps or sunlight.

Compound **1** obtained from the petroleum ether extract of *B. pilosa* aerial parts is rather active towards Gram-positive bacteria but reveals only a weak activity against Gram-negative organisms, dermatophytes, yeasts and molds (Bondarenko et al. [@CR21]; Bondarenko et al. [@CR22]). Several other trials confirmed that PHT can only be active against microorganisms when it is irradiated by ultraviolet light (360--370 nm wavelength) (Geissberger and Sequin [@CR69]; Wat et al. [@CR192]). In fact, most acetylenes are able to produce singlet oxygen in vitro at levels that do not fully account for their toxic effects. For instance, after oxygen removal, compound **1** exhibits no or only a partial decrease in phototoxicity to microorganisms or in the photohemolysis of erythrocytes (Capinera [@CR30]).

The other polyacetylenic compounds **9** and **32** display phytotoxicity in the dark with particular bacteriostatic and fungistatic activities (Geissberger and Sequin [@CR69]; Bohlmann et al. [@CR19]; Ballard [@CR13]; Hoffmann and Hölzl [@CR76]). These results agree with the results of Towers et al. ([@CR179]) who reported that the aerial parts of *B. pilosa* suppress the emergence of *Candida albicans* in the dark. Regarding anti-feedant activity, the early work on compound **1** demonstrated good ovicidal activity in *Drosophila melanogaster* and cercaricidal activity under UV light (Graham et al. [@CR71]; Kagan and Chan [@CR91]; Nakajima and Kawazu [@CR132]). Compound **1** exhibits light-dependent toxicities in larvae of some mosquitos (Kagan [@CR90]). Identified as a major constituent in all parts of *B. pilosa*, compound **1** shows phototoxicity to yeasts and bacteria in the presence of near UV light and strongly suppresses the germination and growth of *F. culmorum* in the presence of UV light, but not in the dark (Capinera [@CR30]). However, Mclachlan et al. ([@CR121]) claimed that this compound displayed anti-feedant activity was apparently unrelated to any phototoxic reaction. Compounds **1** and **15** are present in high concentrations in essential oils of the flowers, leaves, shoots and roots, amounting to 30.7, 40.0, 37.1 and 0.2 %, and 13.3, 13, 7, 20.9 and 0.3 %, respectively (Priestap and Bennett [@CR147]). The compound **1** content in the cuticle of *B. pilosa* can be as high as 600 ppm (Capinera [@CR30]) which may account for various biological activities.

The two flavonoid compounds **86** and **43** enhance the production of IFN-γ by immune cells, activate macrophages and effectively protect mice against *Listeria* infection; compound **43** likely augments IFN-γ expression via a transcriptional up-regulation of T-bet, which protects or treats *Listeria* infection via modulation of IFN-γ expression (Chang et al. [@CR35], [@CR36]). The two fatty acids linoleic and linolenic acid, isolated from petroleum ether extracts of the entire plant, are bacteriostatic at 5--50 ppm (Geissberger and Sequin [@CR69]; Hattori et al. [@CR74]; Nieman [@CR137]). Nevertheless, the entire plant of Egyptian *B. pilosa* contains high contents of fatty acids, such as palmitoleic (53.03 %), palmitic (32.04 %), myristic (6.63 %) and lauric acids (4.9 %) (Sarg et al. [@CR156]). Aqueous or fresh plant extracts may contain sufficient amounts of unsaturated fatty acids to inhibit the growth of bacteria and other microorganisms. However, it is unclear whether these compounds are present as free fatty acids in the fresh plant, or are generated from the enzymatic degradation of oils or fats when the plant material was dried (Geissberger and Sequin [@CR69]; Wagner [@CR188]).

Phytosterols, including compounds **283,** **285,** and **286** (Geissberger and Sequin [@CR69]; Chang et al. [@CR31]) and mixtures of *n*-alkanes obtained from the petroleum ether extract of *B. pilosa* exhibit anti-bacterial activities (Goyal and Gupta [@CR70]). The other major constituents are monoterpenes and sesquiterpenes, such as the compounds **138**, **170**, and **207** which display strong inhibition of several fungal and bacteria strains (Tomczykowa et al. [@CR177]). Compound **118**, a polymer of gallic acid molecules and glucose, is present in the aerial parts of *B. pilosa,* possessing anti-microbial activities (Chung et al. [@CR48]).

Some polyacetylenes, flavonoids and long-chain fatty acids of *B. pilosa* have anti-viral activities; for instance, compounds **87** and **84** hinder the integrase activity of the human immunodeficiency virus (HIV), the HIV-1 protease (Tewtrakul et al. [@CR175]; Xu et al. [@CR197]) and the entry of the severe acute respiratory syndrome coronavirus (SARS virus) into host cells (Yi et al. [@CR199]). Compound **43** significantly suppresses infections by the herpes simplex and polio viruses (Kaij-A-Kamb et al. [@CR92]). Dicaffeoylquinic acids, including compounds **97**--**99** that are isolated from the whole plant, are selective inhibitors of HIV integrase (McDougall et al. [@CR120]) and interfere with poliovirus replication via protease suppression (Hwang et al. [@CR85]).

Anti-cancer activity {#Sec11}
--------------------

Since the 1970s--1980s, in vitro and in vivo studies with *B. pilosa* showed its anti-cancer properties. Mirvish et al. ([@CR122], [@CR124]) fed dried leaves of *B. pilosa* to rats in the \[^3^H\] thymidine incorporation (TI) assay in the esophageal epithelium, which demonstrated a 2.3 fold decrease in the TI into esophageal epithelial DNA. The administration of the dried powder of *B. pilosa* leaves has cocarcinogenic activities induction in rat esophagus tumors (Mirvish et al. [@CR123]). These data agree with more recent results of Wu et al. ([@CR195]) and Chang et al. ([@CR32]) who reported that this plant has strong anti-cancer activity, specifically when used as an anti-angiogenic agent. The ethyl acetate (EtOAc) fraction exerts potent suppressive effects on tube formation and proliferation in human umbilical vein endothelium cells (Wu et al. [@CR195]). Hot water extracts of the whole plant inhibit five human leukemic cell lines, namely L1210, U937, K562, Raji and P3HR1, with a dose-dependent IC~50~ (145--586 µg/mL) (Chang et al. [@CR32]). The hexane extract of *B. pilosa* leaves shows significant inhibition on various human cell lines. The chloroform (CHCl~3~) extract from the aerial parts of the plant provides potent cytotoxicity in vitro in the Tetrazolium Salt and Neutral Red Uptake assays, with IC~50~ = 83.0 and 97.0 µg/mL, respectively. The crude hydroalcoholic extract (HAE) and CHCl~3~ extract significantly reduce the body weight (p \< 0.05), abdominal circumference, tumor volume and viable cell count, but increase the life span of Ehrlich ascites carcinoma tumor-bearing mice by 54 and 42 %, respectively, at dose of 150 mg/kg. They reduce both the serum activity of LDH by 39.5 and 30.6 %, and the GSH content of the tumor liquid by 94.6 and 50.7 %, respectively. The combination of the EtOAc and hydroalcoholic (water: alcohol 6:4) extracts exhibit cytotoxicity with an IC~50~ \<200 µg/mL (Kviecinski et al. [@CR104]; Suffness and Pezzuto [@CR168]). Sundararajan et al. ([@CR170]) reported that the crude methanolic extract and EtOAc fraction of *B. pilosa* express significant cytotoxic effects against the human HeLa and KB carcinoma cell lines. Moreover, Wu et al. ([@CR195]) noted that the EtOAc fraction (25 µg/mL) of the fresh whole *B. pilosa* was also suppressive towards cell proliferation and tube formation in human umbilical vein endothelium cells (HUVEC), and attenuated 80 % of bFGF-promoted HUVEC proliferation. At 500 µg/ml, the crude hot water extracts and *n*-butanol partition stimulated IFN-γ promoter activity by 3- and 6-fold, respectively (Chang et al. [@CR35]).

Research on the anti-cancer activities of the isolated bioactive compounds from *B. pilosa* has received much attention in recent years. The three polyacetylenic compounds **13**, **14**, and **27** (Wu et al. [@CR195]; Wu et al. [@CR196]) derived from the active EA and ethanol fractions of fresh *B. pilosa* exhibit potent activities against HUVEC proliferation (IC~50~ = 2.5 and 0.375 µg/ml, respectively), and upregulats p27 (Kip) or p21 (Cip1) by 2.2- to 3.0-fold increases in Western blot analyses. Notably, compound **13** displayed a more striking influence on preventing tube formation in HUVEC than compound **14** at 2.5 µg/ml. Furthermore, compound **27** completely inhibits endothelial cell formation in collagen gels and migration at 2.5 µg/ml (Wu et al. [@CR195]). Interestingly, such compounds demonstrate highly specific inhibition towards HUVEC proliferation, but did not adversely effect the growth of other tested cell types (Wu et al. [@CR195]). Polyacetylenic compound **12** that is isolated from the methanolic extract of *B. pilosa*, causes normal and transformed human cell lines to overgrow in culture (Alvarez et al. [@CR7]). Interestingly, compound **1** is one of major polyacetylenes obtained from the hexane extract and displays cytotoxicity in various tumor cell lines; particularly in human cancer lines, including HepG~2~ and Caco-2 with IC~50~ = 0.49 and 0.70 µg/ml, respectively (Alvarez et al. [@CR7]; Kumari et al. [@CR101]). It is noteworthy that the early research of Fleischer (Fleisher [@CR66]) reported that 80--85 % of lung cancer patients treated with compound **1**, either pure or as part of an essential oils from *Bidens* species, showed good results. Compound **1** also lacks phototoxic effects towards human skin (Towers et al. [@CR180]) and membrane lesions in human erythrocytes (Macrae et al. [@CR114]). The cytotoxic properties of the polyacetylenes derived from *B. pilosa* are consistent with the fact that polyacetylenes, polyacetylenic glycosides and their derivatives are potential anti-tumor agents (Siddiq and Dembitsky [@CR162]).

Among the flavonoid compounds found in this plant, the nine compounds **45**--**49** and **88**--**91** are derivatives of quercetin. They are inhibiting tumors in rats and significantly decrease both tissue plasminogen activator (t-PA) and urokinase plasminogen activator (u-PA) (Devipriya et al. [@CR55]). However, the specific anti-cancer activities of the isolated quercetin derivatives have neither been evaluated nor fully understood. Compound **43** and centaureidin compound **86** (Chiang et al. [@CR43]) induce tumor cell death via suppression of tubulin polymerization (Beutler et al. [@CR16]). Moreover, these compounds caugment interferon-gamma (IFN-γ) promoter activities by 4-fold and regulate IFN-γ transcription via both the nuclear factor of activated T cells and the nuclear factor-kB in T cells (Chang et al. [@CR35]), which stimulate anti-tumor immunity (Abbas et al. [@CR2]). Compound **87** (Ballard [@CR13]; Hoffmann and Hölzl [@CR75]; Zhao et al. [@CR206]) and butein compound **84** (Ballard [@CR13]; Zhao et al. [@CR206]) induce cell apoptosis in different tumors and possibly detain or block the development of hu*m*an cancer cells in vitro and in vivo (Young et al. [@CR202]; Seelinger et al. [@CR159]; Yit and Das [@CR200]; Seelinger et al. [@CR160]). Other recent studies reveal that compound **86** significantly inhibits the proliferation of a variety of human tumor cells, derived from human breast cancer (Wang et al. [@CR190]), lymphoma (Ramanathan et al. [@CR149]; Lee et al. [@CR108]), melanoma (Iwashita et al. [@CR87]), and colon carcinoma (Kang et al. [@CR93]). Moon et al. (Moon et al. [@CR126]) observed that compound **84** suppresses the growth of human hepatoma cancer cells by inducing G2/M phase arrest and apoptosis, promoting inactivated phosphorylated Cdc2 levels, minimizing Cdc22 kinase activity, and generating reactive oxygen species (ROS); this in turnwas accompanied by c-Jun N-terminal kinase (JNK) activation. However, human hepatoma cancer cells are very sensitive to butein (compound **84**), which inhibits their growth and induces apoptosis. Underlying butein-induced cell cycle arrest is the generation of ROS and subsequent activation of JNK (Moon et al. [@CR126]). Subsequent experiments of Moon et al. (Moon et al. [@CR127]) verified that butein (compound **84**) inhibits constitutive and inducible NF-kB activity; this downregulation leads to suppression of the invasion and angiogenesis of prostate cancer. Tannic acid (compound **118**), a phenolic constituent, exhibits good anti-carcinogenic activity and exerts cancer chemopreventive activity in various animal models (Chung et al. [@CR48]; Nam et al. [@CR133]; Nepka et al. [@CR134]). Compounds **152** and **153** are oxygenated monoterpenoids found in the leaves of *B. pilosa* that induce morphological changes of DNA fragmentation during the treatment of human leukemia HL-60 cells, suggesting an induction of apoptosis (Moteki et al. [@CR129]), and induce caspase-dependent apoptosis in human melanoma M14 WT cells (Calcabrini et al. [@CR27]). However, these compounds are found at low concentrations in the leaves, which may cause insufficient inhibitory effects in human cancer cells, calling for further investigations.

Diabetes mellitus {#Sec12}
-----------------

Diabetes mellitus is characterized by increased serum levels of glucose and represents a serious metabolic disease in terms of its social impact. *B. pilosa* has promising anti-diabetes properties; among the *Bidens* species, *B. pilosa* is popularly used in the treatment of diabetes mellitus worldwide (Connelly [@CR50]; Lans [@CR106]). The extract of dried *B. pilosa* boiled with 15 % water/ethanol for 5 min results in significant hypoglycemic activities in normoglycemic mice and in mildly diabetic mice induced by alloxan with fasting glycemia (200--340 mg/dL), but it was without any effect in severely diabetic mice. This implies that insulin is required as a mediator of the hypoglycemic effects of the plant extracts. In other studies, using water based extracts, a good hypoglycemic effect in mildly alloxan-diabetic mice was reported (Alarcon-Aguilar et al. [@CR5]).

The butanol fraction of the hot water extract derived from the whole plant of *B. pilosa* reveals a 50 % inhibition (IC~50~) of the differentiation of human naïve helper T (Th0) cells into type I helper T (Th1) cells at 200 µg/ml, and completely inhibits cell differentiation at 500 µg/ml, but preferentially enhances their transition into type II helper T (Th2) cells ex vivo (Chang et al. [@CR33]). Injection of the same fraction at a dose of 3 mg/kg to nonobese diabetic (NOD) mice results in a lower incidence of diabetes (33 %) than in control mice (56 %), and halts the initiation of the disease at a dose of 10 mg/kg (Chang et al. [@CR33]). In other experiments, the butanol fractions and the crude extracts of *B. pilosa* are used to treat diabetes mellitus type I; This was triggered by pancreatic islet destruction by immune cells and type II diabetes (Hsu et al. [@CR84]; Ubillas et al. [@CR182]); this fraction can improve Th1 cell-mediated autoimmune diabetes in NOD mice (Chang et al. [@CR34]). In additional studies, the aqueous extract of *B. pilosa* ameliorates diabetes mellitus type II in db/db mice via regulation of insulin secretion and islet protection (Hsu et al. [@CR84]). Chemical analysis has been performed on the methanolic crude extracts, and three variants of *B. pilosa* leaves were investigated in a model of diabetes mellitus type II using db/db mice. The results demonstrate that one variant of *B. pilosa* exerts higher glucose-lowering and insulin-releasing activities in the single-dose and long-term experiments than the two other variants. Three polyacetylenic constituents, compounds **10**, **11**, and **25**, are present in all of the tested plants. It is worth noting that compound **25** was the most effective pure compound isolated from *B. pilosa,* and that *B. pilosa* extracts remarkably reduce the percentage of glycosylated hemoglobin A1c in db/db mice (Chien et al. [@CR46]).

In another trial, a mixture of two polyacetylenic glycosides, compounds **10** and **11** (3:2 ratio) that were derived from the aerial parts of *B. pilosa* (Chang et al. [@CR33]; Ubillas et al. [@CR182]), displays a significant hypoglycemic effect, lowering the harmful influence of type II diabetes mellitus (db/db) in mice (Ubillas et al. [@CR182]). These compounds also exhibit strong preventative effects towards the onset of diabetes and maintain blood sugar levels in NOD mice. Compound **11** is more potent than compound **10**, especially in enhancing the differentiation of Th0 cells into Th2 cells by 34 %, but it inhibits the differentiation of Th0 cells into Th1 cells by 40 % at 15 µg/ml (Chang et al. [@CR33]). It is suggested that the mixture has stronger anti-diabetic effects than either of the single compounds. However, the mechanisms of action of these substances with regards to their effects on type II diabetes are not fully understood.

Compound **25** obtained from fresh *B. pilosa* prevents type I diabetes mellitus in NOD mice through modulation of T cells, by suppressing the proliferation of CD4 + T cells in the spleen and pancreatic lymph nodes of NOD mice and leaving CD8 + T cells untouched (Chang et al. [@CR37]). This compound also stunts the differentiation of type I Th cells but promotes the growth of type II Th cells and enhances GATA-3 transcription. Compound **25** is an effective immunomodulatory prophylactic ingredient towards the development of diabetes mellitus in NOD mice via T cell regulation (Chang et al. [@CR37]). The diabetic action of compound **25** towards type I diabetes mellitus occurs mainly via T cell regulation through a different mechanism than that of other pharmaceutical drugs used for type I diabetes prevention, but it is far less toxic, and less inhibitory on the immune system (Chang et al. [@CR37]). It was also reported that it reduces the differentiation of naive Th0 cells into type I T helper (Th1) cells, but enhances the differentiation of Th0 cells into type II T helper (Th2) cells (Chang et al. [@CR35]). It also inhibits IFN-γ expression in a dose-dependent manner, promotes IL4 in mouse splenocytes ex vivo, and is the most potent polyacetylenic glucoside that regulates T cell differentiation from this plant.

Finally, among the identified flavonoids, butein compound **87** reportedly possesses promising activities for treating complications of diabetes mellitus (Lim et al. [@CR112]). Different extraction methods may result in diverging results with respect to biological activities, as the polyacetylenes in *B. pilosa* are commonly very sensitive and unstable; they also polymerize when concentrated, thereby losing their biological activities. Moreover, the phytochemical contents of *Bidens* species may change when it is grown under different environmental conditions. For example, compound **25**, a potent polyacetylene with potential for treating diabetes mellitus type I, was present in some species of *B. pilosa* plants (Hsu et al. [@CR84]; Ubillas et al. [@CR182]). Interestingly, essential oils of *B. pilosa* from Argentina contained 11.2, 39.5, and 3.3 % of compounds **184**, **169**, and **188**, respectively, but these compounds were not found in the essential oils of *B. pilosa* grown in Japan. In contrast, the main components of *B. pilosa* from Japan are compounds **191** and **231**, composing 2.09 %, and 3.71 % of the essential oils, respectively; these compounds are also detected in *B. pilosa* collected from Argentina (Khanh et al. [@CR96]). The phytotoxic components of *B. pilosa* increase under drought conditions and the concentration of compound **1** significantly varies with geographic and seasonal factors (Cantonwine and Downum [@CR29]; Zeng and Luo [@CR204]). In addition, the production and release of secondary substances of this plant are greatly influenced by the environment. Based on these considerations, it is suggested that the polyacetylenic constituents of *B. pilosa* are the major active phytochemicals against both types of diabetes mellitus.

Arterial hypertension {#Sec13}
---------------------

*B. pilosa* is in traditional use to treat arterial hypertension in many countries. Aqueous and MeOH extracts from the leaves display anti-hypertensive effects in unanaesthetized rats without affecting the pulse (Dimo et al. [@CR56], [@CR58]). The neutral extracts of *B. pilosa* leaves are bioactive in both spontaneously hypertensive and salt-loaded hypertensive rat models and significantly attenuate blood pressure. There are two successive phases of the hypotensive activities. The initial phase is partially suppressed by atropine and enhanced by propranolol. This indicates that *B. pilosa* extract inhibits the first hypotensive phase by affecting the cardiac pumping efficiency, while the second phase is affected by both betareceptor stimulation and muscarinic receptor-mediated vasodilation (Dimo et al. [@CR61]). Subsequent in vitro research by Nguelefack et al. ([@CR135]) evaluated the vasorelaxant effect of a neutral extract of *B. pilosa* leaves on isolated rat aorta contracted with KCl or norepinephrine. The results demonstrate reductions in the aorta resting tone, suppressions of KCl contractions, and substantiation of vasodilatory actions on the tissue (Nguelefack et al. [@CR135]). The neutral extract of the plant obviously has an endothelium-independent relaxant effect, likely resulting from its Ca^2+^ channel-blocking properties (Nguelefack et al. [@CR135]).

In another study, the aqueous and methylene chloride extracts of *B. pilosa* reverse high blood pressure and hypertriglyceridemia in fructose fed rats without altering plasma levels of insulin or glucose (Dimo et al. [@CR59]). This implies that vascular effects are more likely responsible for the hypotensive effect. To understand the effect of the extract of *B. pilosa* on systolic blood pressure and plasma glucose, insulin, cholesterol, triglycerides and creatinine levels in rats with fructose-induced hypertension, as opposed to other kinds of extracts, Dimo et al. ([@CR60]) also reported that MeOH leaf extracts of *B. pilosa* prevent not only the establishment of hypertension and lowered elevated blood pressure levels, but also attenuated elevated plasma insulin levels provoked by the high fructose diet in Wistar rats, but the increase in plasma triglycerides was not attenuated. Dimo et al. ([@CR57]) reported earlier that the aqueous leaf extract of *B. pilosa* had aortic smooth muscle relaxant activity. The chromatographic fractionation of dried *B. pilosa* leaves on Sephadex gel yields several fractions, of which the active F~2~ fraction displays excellent activities on rabbit arterial blood pressure and induces a dose-dependent hypotension (1--25 mg/kg b.w), while it lessened the contractile force of isolated guinea-pig aortas by 10^−12^--10^−1^ mg/ml. The hypotension and vasodilatation elicited by fraction F~2~ are attenuated by propranolol (a *β*-adrenoceptor antagonist), suggesting that fraction F~2~ contains *β*-adrenoceptor antagonist constituents, responsible for the hypotension and the vasodilatation activities (Leandre et al. [@CR107]).

The phytochemicals of *B. pilosa* responsible for its potentially anti-hypertensive activity are not well established. It is known that some flavonoids of various higher plants may be active in cardiovascular diseases such as atherosclerosis, coronary artery disease and arterial hypertension (Fitzpatrick et al. [@CR65]). *B. pilosa* contains flavonoid compounds in large amounts, including bioflavonoid quercetin derivatives (Table [2](#Tab2){ref-type="table"}), which lower elevated blood pressure, reduce cardiac and renal hypertrophy, and cause functional vascular changes in spontaneously hypertensive rats without affecting normotensive Wistar Kyoto rats (Duarte et al. [@CR63]). It is intriguing that the extract contains phytochemicals which, if taken in sufficient quantities, can be useful in the attenuation and prevention of arterial hypertension and hyperinsulinemia induced experimentally by a high fructose diet (Dimo et al. [@CR60]). All plant parts of *B pilosa* are rich in essential oils (Deba et al. [@CR54]; Priestap and Bennett [@CR147]; Zollo et al. [@CR207]; Ogunbinu et al. [@CR140]). Of these, the monoterpenes and phenolics such as compound **149** and the eugenol compound **103** are likely responsible for the anti-hypertensive effects (Interaminense et al. [@CR86]; Lahlou et al. [@CR105]).

Allergies {#Sec14}
---------

The hot water extracts of the dried powder of cellulosine enzyme (BTEC) display potent anti-allergic activities by inhibited histamine release from mast cells. Three compounds, **95**, **48, and 49**, are found in greater amounts in BTEC, suggesting that *B. pilosa* treated with the enzyme possesses good anti-allergic activities (Horiuchi and Seyama [@CR82]). The effects of BTEC fractions on histamine-induced contraction in Guinea pig ileum and the release of histamine in rat peritoneal mast cells were examined, and it was concluded that the anti-allergic activity of BTEC resulted from action on the H1-receptor and the suppression of histamine release. H1-receptor signaling may be hindered by flavonoids, including compounds **41**, **48**, and **49**, contained in BTEC. Additionally, compound **97** and caffeoylquinic derivatives suppress histamine release from mast cells (Matsumoto et al. [@CR119]). Presently, a commercially validated product, ClearGuard^TM^, obtained from three plants including *Cinnamomum zeylanicum, Malpighia glabra,* and *B. pilosa*, is used to treat nasal allergies generated via inflammatory pathways (Corren et al. [@CR51]).

Inflammation {#Sec15}
------------

Inflammation is involved in numerous human diseases and part of the complex biological responses of tissues to harmful stimuli, such as pathogens, damaged cells and irritants, and is. Current research reported the modulation of various inflammatory cytokines, which activate both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) (Connelly [@CR50]). The methanolic extracts of dried leaves of *B. pilosa* display potent immunosuppressive effects on human and murine lymphocytes, stimulated by 5 µg/ml phytohemagglutinin or 100 nM 12-*O*-tetradecanoyl phorbol-13-acetate (TPA), 0.15 µM ionomycin and concavalin A (Con A), or in the mixed leukocyte reaction (IC~50~ = 12.5 to 25 µg/ml). Further, administration of the same extract at 10 mg in mice minimizes the size of the popliteal lymph node (PLN) (1.8 mg) when inflammation is induced by zymosan (Pereira et al. [@CR145]). The EtOAc fraction of fresh *B. pilosa* displays a significant inhibition of LPS-induced NO production in RAW 264.7 cells (IC~50~ = 36 µg/ml) (Chiang et al. [@CR43]). The polyacetylenic compound **28**, isolated from the dried leaves of *B. pilosa*, exhibits anti-inflammatory and immunomodulatory effects in lymphocyte proliferation assays and a zymosan-induced arthritis mouse model (Pereira et al. [@CR145]). Specifically, compound **28** is 10-fold more potent than the original MeOH extract in blocking both human and murine lymphocyte proliferation (IC~50~ = 1.25 and 2.5 µg/ml, respectively) (Pereira et al. [@CR145]). The *B. pilosa* extract has immunosuppressive effects due to the presence of the polyacetylenes (Pereira et al. [@CR145]). The proliferative responses of lymphocytes to various stimuli are completely suppressed by a methanolic extract of *B. pilosa*. The treatment of mice with *B. pilosa* for 5 days strongly blocks the increase in PLN weight, presumably by suppressing lymphocyte proliferation. These data suggest l that *B. pilosa* hass anti-inflammatory properties, suitable to be used as possible source of promising anti-inflammatory drugs (Geissberger and Sequin [@CR69]; Pereira et al. [@CR145]).

Boiling water extracts of the aerial parts of *B. pilosa* that were treated with the BTEC display anti-inflammatory properties. Suspensions of *B.* *pilosa* samples in 0.25 % carboxy-methyl-cellulose sodium (CMC-Na) suppress in vivo after oral administration in mice the production of IgE ten days after immunization with DNP-ascaris (Bushnell et al. [@CR26]). Dried powder of *B. pilosa* aerial parts also severely inhibits progressive gastric mucosal lesions induced by HCl/EtOH (Horiuchi et al. [@CR83]). The hot water extract of the dried aerial parts of *B. pilosa* causes inflammation in normal human dermal fibroblasts with interleukin (IL)-1 *β*. It inhibits COX-2 expression and PG2 production (Yoshida et al. [@CR201]). The anti-inflammatory effects of BTEC are ascribed to the presence of phenolic and flavonoid constituents, such as compounds **48**, **49**, and **95**, which are present in higher amounts than in hot water extracts (Horiuchi and Seyama [@CR82]). *B. pilosa* displays cytoprotective activities towards the gastric mucosa for the inhibition of COX-2 and shows anti-ulcerogenic activity (Horiuchi et al. [@CR83]).

The other three polyacetylenic compounds **10**, **11** and **25**, are known to suppress the production of several inflammatory cytokines, such as IFN-γ, but they also enhance the production of anti-inflammatory cytokines, such as IL-4 (Chang et al. [@CR33], [@CR37]). Ethyl caffeate compound **104**, a natural phenolic constituent, is present in the fresh whole plant; its anti-inflammatory activity has been evaluated in vitro in lipopolysaccharide (LPS)-stimulated macrophages and in vivo using the TPA-treated mouse skin system and cell lines (Chiang et al. [@CR44]). Compound **104** also exhibits significant inhibition of LPS-induced nitric oxide production (IC~50~ = 5.5 µg/ml) with a remarkable suppression of COX-2 expression. Additionally, ethyl caffeate at a dose of 1 µg/ml drastically decreases the expression of iNOS mRNA in LPS-treated macrophages (Chiang et al. [@CR44]). The production of PGE2, a growth-promoting factor in certain carcinoma cell lines and a mediator of inflammation, is impressively suppressed by compound **104** (Chiang et al. [@CR44]).

Several flavonoid compounds obtained from the leaves of *B. pilosa*, including compounds **40**, **46**, **47**, **49**, **83,** and **87**, possess significant anti-inflammatory activities (Geissberger and Sequin [@CR69]; Seelinger et al. [@CR160]; Alcaraz and Jimenez [@CR6]; Maki [@CR116]). Quercetin is a ubiquitous flavonoid found in numerous plants and, often linked to sugars, such as in compounds **41** and **48**; this prevents allergen-induced and platelet-activating factor-induced bronchial obstruction as well as bronchial hyperreactivity in a guinea pig model of asthma (Dorsch et al. [@CR62]; Rogerio et al. [@CR152]). Compound **48** exhibits anti-asthmatic activities by suppressing carbachol- and leukotriene-D4-induced contractions in guinea pig airways (Fernandez et al. [@CR64]). Another study has reported that both quercetin and compound **48** are effective suppressors of eosinophilic inflammation in a murine model of asthma (Rogerio et al. [@CR152]). The two pentacyclic triterpenes, compounds **217** and **219**, found in the aerial parts of *B. pilosa* (Chen et al. [@CR40]) exhibit anti-inflammatory activities (Chaturvedi et al. [@CR38]). Butein compound **84** inhibits inflammatory responses, such as the production of lipopolysaccharide-induced pro-inflammatory cytokines and nitric oxide expression (Jung et al. [@CR89]; Lee et al. [@CR109]). In addition, the methanolic extract of the whole plant of *B. pilosa* exhibits anti-pyretic activities in vivo that are comparable to paracetamol in the rabbit pyrogen test (Sundararajan et al. [@CR170]).

Moreover, Lee et al. ([@CR110]) reported that this butein compound has the potential to influence intestinal inflammatory diseases, as it blocks effects on TNF-α-induced interleukin 8 (IL-8) and MMP-7 expression in HT-29 cells. However, it is questionable if the small amounts of these compounds present in the plant juice/water extracts, or other unidentified compounds may be responsible for the anti-inflammatory activities. *B. pilosa* has promising potent anti-inflammatory activities and should be developed as a potential anti-inflammatory drug.

Antioxidant activities {#Sec16}
----------------------

*B. pilosa* exets good anti-oxidant activities (Chiang et al. [@CR43]; Deba et al. [@CR54]; Kusano et al. [@CR103]; Muchuweti et al. [@CR130]). The methanolic extracts of *B. pilosa* aerial parts exhibit remarkable antioxidant properties in 1,1-diphenyl-2-picryl-hydrazyl (DPPH), reducing power, and in *β*-carotene and lipid peroxidation assays. Fifteen common phenolic acids including compounds **95**, **101**--**115**, and **119** are identified in *B. pilosa.* Compound **95** is present inhighest amounts in the leaves, stems and roots (117.4, 298.7, and 350.3 µg g^−1^, respectively), followed by compound **113** (18.5, 32.9 and 29.6 µg g^−1^, respectively), and compound **105** (Table [4](#Tab4){ref-type="table"}) (6.1, 6.2 and 37.1 µg g^−1^, respectively) (Khanh et al. [@CR96]; Deba et al. [@CR54]). These substances are likely responsible for the anti-oxidant activities of *B. pilosa* (Deba et al. [@CR53]; Muchuweti et al. [@CR130]). The hot water and ethanol extracts of the aerial parts of *B. pilosa* from Japan show significant anti-oxidant activity in comparison with trolox C, a water-soluble tocopheroxyl vitamin E analogue (Kusano et al. [@CR103]; Ramos et al. [@CR150]). In addition, potent anti-oxidant fractions are in some coffee tannins, caffeic acid derivatives and flavonoids, including compounds **41**, **42**, **45**, **48**, **49,** and **97**--**99** (Kusano et al. [@CR103]). Ethanol and EtOAc/ethanol extracts of *B. pilosa* protect normal human erythrocytes against oxidative damage in vitro (Yang et al. [@CR198]). The oxidative hemolysis and lipid/protein peroxidation of erythrocytes induced by the aqueous peroxyl radical 2,2′-azobis (2-amidinopropane) dihydrochloride (AAPH) are inhibited by both extracts at 50--150 and 25--75 µg/ml, respectively. However, the efficacy is dose and time dependent. These extracts also attenuate the decline of superoxide dismutase (SOD) activity and the depletion of cytosolic glutathione (GSH) and ATP in erythrocytes (Yang et al. [@CR198]).

Chemical analyses examining the EtOH and EA/EtOH extracts detected a number of caffeoyl derivatives, flavonoids, polyacetylenes and terpene derivatives that exert antioxidant activities, including compounds **10**--**11**, **14**, **74**, **97**--**99**, and **104** (Wang et al. [@CR189]; Chiang et al. [@CR43]; [@CR44]; Wu et al. [@CR195]; Chang et al. [@CR33]; Yang et al. [@CR198]). These compounds display significant anti-oxidant activities for both in vitro and in vivo assays (Chiang et al. [@CR44]; Arora et al. [@CR10]; Morand et al. [@CR128]; Rose and Kasum [@CR154]; Sinmonetti et al. [@CR164]; CIMAP [@CR49]). An infusion of extracts derived from fresh aerial parts of *B. pilosa* in Cuba halves the hemolysis induced by AAPH at 6 µl, which corresponds to an IC~50~ of 1.19 mg of dry weight per ml of infusion. Additionally, the oxidative hemolysis of erythrocytes induced by AAPH is drastically inhibited by an aqueous infusion of *B. pilosa*, a very active anti-oxidant, exerting protective effects at low concentrations (Abajo et al. [@CR1]). Studies on hepatoprotective effects reported that total flavonoids of *B. pilosa* (TFB) remarkably reduce carbon tetrachloride (CCl~4~)-induced liver injury in rats, and restore hepatic SOD, glutathione peroxidase (GSH-Px) activities in mice with acute liver injury; this might be due to their anti-oxidant properties, free radical-scavenging activities and inhibition of NF-kB activation (Yuan et al. [@CR203]).

The EtOAc and butanolic fractions of a successive partition of 70 % ethanol extract of fresh *B. pilosa* show significant DPPH free radical-scavenging activity (IC~50~ = 14--17 µg/ml) and potent suppression of LPS-mediated nitric oxide production in RAW 264.7 cells (Chiang et al. [@CR43]). Six phenolic and flavonoid compounds were isolated from the BuOH fraction, including compounds **52**, **53**, and **96**--**99**, which represent the major anti-oxidative constituents of the *B. pilosa* extract (Chiang et al. [@CR43]). Based on structure analyses of the anti-oxidant activity, it substitution of the C~3~ hydroxyl group with glycosides, for example in the cases of compounds **52** and **53**, results in stronger inhibition based on IC~50~ values for DPPH radicals relative to that of quercetin, which only contains free hydroxyl groups at the C~3~ position.

Compounds **43** and **44** contain substitutions with either glycosides or methoxy groups at their C~3~, C~6~, C~7~, C~3′~ and/or C~4′~ positions and display lower free radical scavenging activities when comparing to the 2 quercetin compounds (Chiang et al. [@CR43]). Compounds **95** and **117**, which contain *para*- and *ortho*-hydroxyl groups, display excellent anti-oxidant activities (Chiang et al. [@CR43]; Chen and Ho [@CR39]; Gulcin et al. [@CR73]). Compound **84**, which is found in most parts of *B. pilosa*, is a typical example of a very powerful anti-oxidant, which has more potent activities against DPPH radicals than α-tocopherol (Chen et al. [@CR41]). The anti-oxidant mechanism of compound **84** is due to the H-atom transfer at the 4-OH, due to its lowest bond dissociation energy, with the B-ring of butein possessing a strong hydrogen-donating ability (Chen et al. [@CR41]).

Another example of a highly active anti-oxidant is compound **87**, a flavone found in the entire *B. pilosa* plant. However, this compound exhibits a lower pro-oxidant potential than quercetin. The *O*-di-OH catechol group of the B ring can chelate metal ions and contributes significantly to its anti-oxidant activity (Seelinger et al. [@CR160]). Compound **295** is a potent antioxidant that protects cell membranes against oxidative damage in vivo (Shi et al. [@CR161]; Palan et al. [@CR143]). The anti-oxidant activities of the essential oils of leaves and flowers of *B. pilosa* are superior to all water based extracts. The leaf and flower essential oils exhibit suppressive activities toward the stable free radical DPPH, resulting in the formation of the yellow-colored diphenylpicylhydrazine (IC~50~ = 47 and 50 µg/ml, respectively), while the IC~50~ values of the synthetic and natural anti-oxidant activities are 21 and 36 µg/ml, respectively. This suggests that the flowers of *B. pilosa* possess potent anti-oxidant activities, but these are lower than those of synthetic anti-oxidants (Deba et al. [@CR54]). Thus, *B. pilosa* is a major source of polyphenolics, caffeoylquinic acid derivatives, and flavonoid glycosides, which should be exploited as potential antioxidant drugs.

Gastrointestinal tract {#Sec17}
----------------------

The ethanolic extract of *B. pilosa* derived from its aerial parts (0.5--2.0 g/kg) minimize gastric juice volume, acid secretion, and pepsin secretion in pylorus-ligated rats. A similar extract of *B. pilosa* exhibits anti-ulcer activities against indomethacin-induced gastric lesions. The presence of quercetin in the plant has been detected by high performance liquid chromatography (HPLC) analysis; it has anti-ulcer and anti-secretory potency (Alvarez et al. [@CR8]; Alarcon de la Lastra et al. [@CR4]). The effects of the MeOH, cyclohexane and methylene chloride extracts of the leaves of *B. pilosa* in various gastric ulcer models in rats have also been investigated. The methylene chloride extract displays \>46 % and approximately 100 % inhibition of lesion formation at doses of 500 and 750 mg/kg, respectively. The MeOH and cyclohexane extracts displayed 41 and 46 %, inhibition, respectively. The percentage of inhibition is proportional to the applied dose (Tan et al. [@CR172]). However, the ethanol extract of the leaves of *B. pilosa* substantially inhibits prostaglandin synthesis in vitro (Jager et al. [@CR88]). It implies that the prostaglandin-mediated cytoprotective action is concentrated in the methylene chloride extract (Tan et al. [@CR172]).

Three variants of *B. pilosa,* including *B. pilosa* L. var *Minor,* protect the liver from injury by various hepatotoxins and have potential as broad-spectrum hepatoprotective agents (Chih et al. [@CR47]). The aqueous extract of *B. pilosa* displayed protection against liver damage induced by chronic obstructive cholestasis in young rats and was proposed for use as a treatment of an analogous disease in children (Suzigan et al. [@CR171]). Some phytosterols, such as *β*-sitosterols, compounds **285** and **286**, have anti-nociceptive effects (Santos et al. [@CR155]).

Reproductive tract {#Sec18}
------------------

In some in vitro and in vivo studies, boiling water extracts of dried leaves of *B. pilosa* displayed higher oxytocic/uterotonic and estrogenic/uterotrophic effects than other organic extracts (Frida et al. [@CR68]). These results explain why *B. pilosa* leaves are used as a folk medicine to enhance labor in many countries. Due to their oxytocic effects, decoctions of *B. pilosa* should not be taken by pregnant women (Noumi et al. [@CR138]). In addition, the F~3~ chromatographic fraction of the leaf extract of *B. pilosa* induces hypotension followed by the death of rabbits at high doses (Leandre et al. [@CR107]). The extract of the leaves has been used experimentally against snake venoms and found to slightly antagonize *D. jamesoni* venom and had no effects on anti-venom serum (Marchant [@CR117]). The methanolic extract of the whole plant of *B. pilosa* exhibited a comparable anti-pyretic activity in vivo to paracetamol in the rabbit pyrogen test (Sundararajan et al. [@CR170]).

Experimental and human toxicology {#Sec19}
=================================

Toxicology studies require assessments in experimental animals and humans, but through examinations in sufficient numbers are still lacking which could classify *B. pilosa* as non-toxic and safe. Nevertheless, some preliminary specific experimental studies provided no evidence of toxicity when a dosage of 1 g per kg of body weight was injected into mice (Taylor [@CR173]). Also, orally administrated infusions of the ground powder of *B. pilosa* aerial parts at a concentration of 100 mg/mL is not toxic to rats at a dose limit of 2000 mg/kg over 28 days (WHO [@CR193]). Ethanol and water based extracts of *B. pilosa* leaves display negligible toxic effects on rats in vivo (Klayman [@CR97]). Dermal edema or erythema are not observed with repeated doses during consecutive experiments (WHO [@CR193]). Tea made from the aerial parts of *B. pilosa* by infusion and decoction has genotoxic effects in vitro, which suggests that using *B. pilosa* infusions at a dose of 40 µl/ml culture medium should be avoided, along with a dose of 2 mg/ml of extract (Costa et al. [@CR52]). Nevertheless, the origin of the collected samples in the above study is questionable, because medicinal herbs may be harmful if they are grown in polluted areas. In particular, some recent studies have reported that *B. pilosa* is not only a hyperaccumulator of cadmium (Cd) and metals but also an excluder of arsenic (As) being thereby an excellent environmental bioremediator of As and Cd (Abe et al. [@CR3]; Sun et al. [@CR169]) but harmful for humans. For instance, under the co-contamination of As and Cd, the concentrations of As and Cd accumulated in the tissues of *B. pilosa* increased with increasing As and Cd contents in the soil. Specifically, the level of Cd in stems and leaves reached 103 and 110 mg/kg, respectively, when Cd was present in soil at 10 mg/kg (Sun et al. [@CR169]). Presently, there is no report on the human chelation effects of this plant. Therefore, collection and harvesting of this plant for medical use must be done carefully, and the plant material should be assayed if there is any doubt regarding safety due to its origins (Connelly [@CR50]). Additionally, herb sources should always be considered as the pharmacological actions of plants are significantly influenced by many environmental factors, such as the weather conditions, soil type, and time of plant harvest.

In humans, ClearGuard^TM^ is a marketed anti-allergic product of *B. pilosa* that is considered safe similar to a pharmaceutical drug such as loratadine (Connelly [@CR50]; Corren et al. [@CR51]). Potawale et al. ([@CR146]) and Young et al. ([@CR202]) suggested that the use of dried *B. pilosa* twice per day (2 g per person) is safe. However, more studies in humans are needed, although *B. pilosa* has a long history of traditional use without reports of any serious side effects, suggesting that *B. pilosa* likely is safe.

Tentative clinical implications {#Sec20}
===============================

A large section of the population in developing countries relies primarily on experience and traditional practitioners as their primary source of health care, and this includes the use of herbs such as *B. pilosa* with its PHT (compound **1**), a fascinating active compound exhibits excellent activities in various pharmacological assays. Clearly, *B. pilosa* has gastric anti-secretory, anti-ulcer, anti-allergic, anti-diarrhea, muscle relaxant, pain-relieving, anti-histamine, anti-hepatic, and anti-pyretic activities (Khanh et al. [@CR96]). However, valid clinical studies with criteria of evidence based medicine to establish efficacy and a positive benefit/risk profile are not available for *B. pilosa*. Lack of valid clinical trials is also a characteristic feature in traditional Chinese medicine TCM (Tescheke et al. [@CR174]), which impedes wide spread use of TCM and also of *B. pilosa*. In addition, the collection and harvesting of the herb for medicinal purposes must be cautioned, and plant material must be assayed, if there are any doubts regarding its origins because the chemical constituents and pharmacological activities of this herb may vary with the environmental conditions. At present, more accurate scientific evaluations are needed to verify the worldwide medicinal uses of this plant and to determine the pharmacological activities of each compound in isolation and in mixtures.

Conclusions {#Sec21}
===========

Worldwide actual studies and over the past 40 years focused on the pharmacological and phytochemical properties of *B. pilosa* to authenticate its use in traditional folk medicine. The use of *B. pilosa* as a possible herbal drug is feasible but valid human clinical trials to establish efficacy are still rare. Various types of preparations, extraction methods and numerous single compounds derived from the different parts of this plant have been demonstrated to possess a wide range of pharmacological and biological effects. Polyacetylenes and their derivatives are among the most biologically active compounds isolated in high quantities. In particular, PHT (compound **1**) is responsible for the major pharmacological effects. Other biologically active compounds belonging to the group of flavonoids, phenolic acids, terpenes, phytosterols, and fatty acids have been implicated in the pharmacological actions of this plant.
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